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Abstract 
 
Malaria remains one of the most common causes of illness and death in developing 
countries.1  The development of new drugs to combat the disease is becoming one of 
the fastest growing research areas.  Hydroxypiperaquine (HPQ) is an antimalarial 
bisquinoline compound related to the emerging antimalarial drug Piperaquine (PQ).2 
Various research programs are being conducted internationally in efforts to prepare 
PQ for possible clinical use in combination with artemisinin derivatives. The 
hydroxy compound (HPQ) has been described in the Chinese literature but no data 
exists for this compound within the Western literature.3  The primary aim of this 
research project was to synthesise Hydroxypiperaquine via alternative synthetic 
pathways to that briefly described by Xu et al3 by exploring various synthetic 
strategies based on literature synthetic procedures involving similar compounds.  
HPQ was synthesised through a three step synthetic process.  In the first step, tertiary 
butoxy carbonyl (tBOC) piperazine was coupled with 4,7-dichloroquine (4,7-DCQ) 
to produce the intermediate 7-chloro-4-(tBOC piperazin-1-yl)quinoline.  The second 
synthetic step involved the deprotection of 7-chloro-4-(tBOCpiperazinyl)quinoline to 
remove the tertiary butoxy carbonyl (tBOC) protecting group.  The deprotected 
intermediate, 7-chloro-4-(piperazin-1-yl)quinoline, was subsequently reacted with 
1,3-dichloropropanol in 1-pentanol to yield HPQ in the third step. This three step 
synthetic approach provides an alternative and efficient process to synthesise HPQ.  
The research provides important and specific details for the synthetic methodology 
involved in the synthesis of HPQ for future synthetic and biological research. 
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“Malaria is a disease that is both preventable and curable, yet a child dies of 
malaria every 30 seconds”. 4 
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1   INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 Malaria 
Malaria is a major global health issue leading to the death of up to 3 million people 
annually.5  Almost 40% of the world lives under the constant threat of contracting the 
disease.  In 2003, according to the World Health Organization 350–500 million 
people worldwide became ill with malaria.6  Malaria is an infection caused by the 
parasitic protozoan of genera Plasmodium and transmitted into humans via the 
mosquito.  
 
1.1.1 Cause of Malaria 
Malaria is caused by the protozoan Plasmodium (P), four species of which infect 
humans.  These are P. falciparum, P. vivax, P. ovale and P. malariae.  These parasites 
differ in morphology and have different life cycles.  Almost all malaria related deaths 
and disease are caused by P. falciparum.7  P. falciparum is the most pathogenic 
species causing malaria in humans; the febrile attacks caused by its infection lasting 
48 hours.  The pathogenicity of P. falciparum combined with its ability to acquire 
resistance to multiple drugs makes it the most dangerous species to humans.  Most 
deaths occur due to a complication of the infection by P. falciparum in which infected 
erythrocytes adhere to the vascular endothelium of the post-capillary venules in the 
brain.8, 9  P. vivax is the most globally widespread form of malaria prevailing in 
Central America, the Middle East, India and various countries in South East Asia.10 
This infection is rarely fatal but has the ability to form dormant hypnozoites in the 
liver, which can cause relapse (P. ovale can form dormant hypnozoites though relapse 
is very rare 10).  Similar to P. falciparum, both P. vivax and P. ovale exhibit a 48-hour 
cycle of fever.  P. malariae causes benign quartan malaria with a febrile cycle of 72 
hours.9, 10  Its distribution is similar to P. falciparum but it only causes a very mild 
form of infection.        
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1.1.2 Transmission of Malaria 
The vector responsible for malarial transmission is the female Anophelene mosquito 
(Figure 1).9  The mosquito serves as a co-host for the disease and part of the parasitic 
life cycle is completed within its gut.  As the mosquito injects its proboscis into a 
human blood capillary it salivates to dilute the blood and injects both anticoagulants 
and the parasitic sporozoites into the bloodstream. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Female Anopheles mosquito 
 
Malaria can also be transmitted by human blood transfusions and through the use of 
infected hypodermic needles though this is very rare.7, 9 
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1.1.3 Life Cycle of the Malarial Parasite 
Figure 2 illustrates the lifecycle of the malarial parasite which begins in humans when 
an infected female mosquito bites, withdrawing blood and simultaneously injecting 
sporozoite-containing saliva directly into the bloodstream.7, 9   
 
 
Figure 2  Life cycle of the malarial parasite 11 
 
With each bite the mosquito injects about 20 to 30 sporozoites into the circulatory 
system. The sporozoites multiply in the liver to form numerous merozoites.7, 9  Within 
a week the merozoites re-enter the bloodstream where within the red blood cells 
(erythrocytes) they develop through the ring, trophozoite, and schizont stages (as 
shown on the right hand side of Figure 2).  During these stages the infected 
erythrocyte does not come under attack from the immune system thereby shielding the 
parasite.  Parasite growth is supported by the ingestion of the host’s haemoglobin.  
The cycle of asexual division into daughter merozoites, their maturation to schizonts 
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and the release of toxins takes up to 48 hours and is accompanied by fever, which is 
typically cyclic.  At this stage merozoites can invade new erythrocytes and the 
erythrocytic cycle recommences.7,9  After several cycles, the intraerythrocytic 
parasites can develop into sexual stage gametocytes.  These gametocytes are ingested 
when a mosquito bites an infected individual and the sexual life cycle commences in 
the mosquito gut where the gametocytes form fused oocytes.  These oocytes can later 
form sporozoites that travel to the mosquito’s salivary glands ready to reinfect another 
human host.7-9  
 
1.2 Drugs employed in Malarial Therapy 
The antimalarials drugs used globally are divided into the following five classes.5  
• Quinolines (includes quinoline arylaminoalcohols) 
• Antifolates  
• Artemisinin derivatives 
• Hydroxynaphthaquinones 
• Antibacterial Agents  
 
1.2.1 Quinolines  
One of the first agents used for the treatment of malaria was the bark of cinchona tree, 
which was introduced to Europe from South America in the 17th century.9  The active 
component contained in the bark is a quinoline based compound, Quinine (Figure 3).   
Quinine acts primarily as a blood schizonticide and it has little effect on sporozoites 
or pre-erythrocytic forms of malarial parasites. 
 
N
N
H3CO
H
HO
H
H
 
Figure 3 Chemical structure of Quinine 
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Quinolines which include for the most part the quinoline-based arylaminoalcohols can 
act on the malarial parasite via various pharmacological mechanisms.   They are able 
to act on different stages of the parasitic life cycle.   Chloroquine (Figure 4A) and 
other 4-aminoquinoline derivatives have been shown to inhibit DNA replication and 
RNA synthesis in the nucleus of the protozoal parasite.8 
 
 
 
 
 
 
 
 
Figure 4 Chemical structures of Chloroquine (A) and Mefloquine (B) 
 
Chloroquine is active on those stages of the parasitic life cycle in which the parasite 
actively degrades haemoglobin.  Studies have shown swelling of the parasitic food 
vacuole and undigested haemoglobin in the parasitic endocytic vesicles suggesting 
that the food vacuole is the site of action of the quinoline antimalarials.8, 12  The 
parasitic food vacuole is acidic in nature and the accumulation of basic compounds 
such as chloroquine and other aminoquinolines increases vacuole pH forcing 
unfavourable conditions for parasitic development and growth.  The malarial parasite 
resides in the erythrocyte which contains high quantities of haemoglobin.  The 
parasite feeds on the proteinicious globulin but the heme cofactor is very toxic to the 
parasite.   To decrease the toxicity of heme, the parasite polymerises the heme to non-
toxic haemozoin which is also known as malarial pigment.  Chloroquine and most 
other quinoline antimalarials inhibit the heme polymerisation process thereby killing 
the parasite with an accumulation of toxic heme.8, 13, 14  Mefloquine (Figure 4B) and 
Quinine are classified as quinolinementhols and have the same mechanism of action 
as chloroquine.  Although mefloquine’s mechanism of action is similar to chloroquine, 
studies suggest that the exact step in the parasite feeding process which it interferes 
with may be different.8  The quinoline-based drug Chloroquine (CQ) will be discussed 
in detail in Section 1.3.  
N
CF3
HO
N
H
CF3
 
N
HN
N
Cl
 
 
A 
B 
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1.2.2 Antifolates 
Dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) are key 
enzymes in parasitic de novo folate biosynthesis and their inhibition inhibits 
biosynthesis of pyrimidines and purines in the parasite.1  Antifolate drugs inhibit 
either dihydrofolate reductase (DHFR) e.g. Pyrimethamine (Figure 5C) and Proguanil 
(Fig 5B), or dihydropteroate synthase (DHPS) e.g. Sulphodoxine.  In P. falciparum, 
DHFR is a key enzyme in the redox cycle for the production of tetrahydrofolate 
which is required for essential parasitic thymidine and metheonine biosynthesis.  The 
drugs Pyrimethamine and Proguanil act by inhibiting DHFR.  Antifolate drugs are 
usually used in combination with other antimalarial agents e.g. 4-Aminoquinolines 
and Atavaquone.  When DHFR or DHPS inhibitors are used alone resistance in 
parasites becomes rapidly evident due to single point mutations in the genes encoding 
for these enzymes.15 
 
S
NH2
OO
NH2
NH
NHHN
NHHN
Cl
N
H2N
N
NH2
Cl
A B C
 
Figure 5 Chemical structures of Dapsone (A), Proguanil (B) and Pyrimethamine 
(C) 
 
Pyrimethamine acts by inhibiting plasmodial dihydrofolate reductase (DHFR) whilst 
the sulpha drugs, with which it is combined e.g. Sulphodoxine, inhibit 
dihydropteroate synthase (DHPS).  The concomitant blockage of dihydro folate 
synthesis and the inhibition of DHFR make the combination of DHPS and DHFR 
inhibitors synergistic – one inhibitor potentiates the activity of the other.16  The new 
combination of Chlorproguanil and Dapsone (Figure 5A) known as the antimalarial 
formulation Lap Dap17 was developed to counterbalance the resistance to 
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Sulphodoxine-Pyrimethamine.  These drugs were combined in order to obtain an 
antifolate combination with shorter in vivo residence time than Sulphodoxine -
Pyrimethamine hence lowering the probability of selecting resistant parasites.18 
Clinical studies have shown good activity against strains resistant to the previous 
combination of Sulphodoxine–Pyrimethamine.19  Resistance to antifolate drugs is due 
to an effective efflux mechanism that the parasite develops.  In order to overcome this, 
new strategies such as the addition of Probenecid to the combination has been 
employed.  This drug in particular serves to inhibit the drug efflux mechanism within 
the parasite.19 
 
1.2.3 Artemisinin and its derivatives  
The natural product Artemisinin (Figure 6) also known as Quinghaosu in China, (its 
country of origin) is derived from Artemisia annua, the sweet wormwood plant.  A 
cold water extract of this plant has been used in traditional Chinese medicine for 
many years as a treatment for malarial fever.1, 5, 20 
 
 
 
 
 
 
 
 
 
 
Figure 6 Chemical structure of Artemisinin  
 
The active ingredient Artemisinin and its synthetic derivatives (artesunate, artemether, 
and arteether) have been used for the treatment of malaria since 1970 (when 
Artemisinin was first isolated).1  Artemisinin reduces overall malaria transmission and 
decrease mortality rate due to rapid parasite clearance and targeting of gametocytes in 
the early developmental stage.21  Artemisinin is biotransformed rapidly but does not 
O
O
H
O
O
O
HH
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form any active metabolites.  Artesunate and artemether are biotransformed to the 
active metabolite dihydroartemisinin (DHA) in vivo which has an elimination half life 
of approximately 1 hour.  This ultra short elimination half life makes artemisinin 
derivatives unsuitable for sole therapy and enhances the opportunity of parasitic 
resistance. Artemisinin-based combination therapies (ACTs) were developed to 
overcome this issue and are currently the best anti-malarial drugs available.20-22  
Artemisinins have become very popular in combination therapies and as of 2005 have 
been adopted in national malaria campaigns by 43 countries.4  
 
1.2.4 Hydroxynaphthaquinones  
Hydroxynaphthaquinones are potent inhibitors of mitochondrial electron transport 
processes, which compete with the biological electron carrier ubiquinone.23  In 
mammalian cells, ubiquinone-linked dehydrogenases are involved in energy 
generation via the synthesis of Adenosine triphosphate (ATP).65  Atovaquone (Figure 
7), a ubiquinone analogue binds to the cytochrome bc1 complex of the parasite 
mitochondrial electron transport chain and inhibits cytochrome c reductase activity in 
P. falciparum. 1, 23  
 
 
 
 
 
 
 
 
 
Figure 7 Chemical structure of Atovaquone 
 
 Atovaquone acts synergistically with Proguanil to collapse the parasite mitochondrial 
membrane potential.23  This drug combination has been used very successfully in both 
malarial treatment and prophylaxis.15  The site of action of hydroxynaphthaquinones 
is very different from other antimalarial classes.   In spite of the above, resistance has 
emerged primarily due to point mutations in the cytochrome b gene of the parasite 
O
O
Cl
OH
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which are much more rapid than the parasite mutations which confer chloroquine 
resistance.23, 24  
 
1.2.5 Antibacterial Agents 
Tetracycline (Figure 8) and Doxycycline are the most commonly used antibiotic 
antimalarials.25  They have been used in combination mostly with quinine and 
chloroquine.25-27  Antimalarial combinations with tetracycline have been shown to 
have good activity against both chloroquine resistant and chloroquine sensitive P. 
falciparum malaria.25-27  However, combinations of tetracycline have not been proven 
safe in pregnancy therefore their use has been limited.15  Various antibacterial drugs 
such as sulphonamides, clindamycin, rifampin and desferrioxamine have been used 
alone or in combination with quinolines but their activity is not exemplary when 
compared to the first line drugs e.g. Artemisinins.25  Recent studies have shown that 
macrolide antibiotics such as erythromycin and azithromycin can also be used in 
combination with quinine and chloroquine.25  The rationale for these combinations is 
the safety of macrolides in pregnancy.28  Attempts to combine macrolides with 
artemisinin derivatives have not yielded satisfactory clinical results because of the 
marked antagonistic activity of these drugs.29 
 
 
 
 
 
 
 
Figure 8 Chemical structure of Tetracycline 
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1.3 Chloroquine 
Chloroquine (CQ, Figure 4A, Page 6) was introduced during the Second World War 
in 1943 by US researchers.13  It was originally synthesized in 1934 by the Bayer 
Company (Germany) and was called Resochin.30  Resochin was initially thought too 
toxic for clinical use and was ignored by the pharmaceutical establishment for a 
decade.  However, during World War II allied troops captured a supply of the related 
drug Sontaquine, and began a re-evaluation of the two drugs.  Resochin was found to 
be safe at therapeutic concentrations and was renamed chloroquine and underwent 
clinical trials in 1943.  Since that time it has proved to be a highly effective, safe and a 
well tolerated drug for both the treatment and prophylaxis of malaria.1, 13 
 
1.3.1 Chemical Properties of Chloroquine  
 CQ or 7-Chloro-4-(4-diethylamino-1-methylbutylamino)quinoline is a 
aminoquinoline alkaloid with potent antimalarial activity.9  It is a weak base 
containing amine groups with  pKa (8.1, 9.9) values in the physiological range.31  It 
exists in 3 different isoforms, the dextrorotatory d, levorotatory l and a racemic 
mixture of both dl all of which have equal potency.9  CQ is slightly soluble in water, 
soluble in chloroform, ether and dilute acids.  CQ is clinically available as 
chloroquine diphosphate, phosphate, hydrochloride and dihydrochloride.32  The most 
common form, CQ diphosphate is readily soluble in water but practically insoluble in 
alcohol, methanol, ether and chloroform.  Aqueous solutions for injection 
formulations of CQ often employ chloroquine diphosphate.31 
 
1.3.2 Mechanism of Action of Chloroquine 
CQ is a potent schizonticide, active against the erythrocytic forms of all strains of 
plasmodia that cause malaria in humans.7, 9, 13  It has some gametocytocidal activity in 
P.vivax, P. ovale and P. malariae, but does not have an effect on sporozoites or 
hypnozoites within the liver.13 Despite extensive research, the definitive mechanism 
of action of CQ is still unknown, although a number of facts related to its action are 
now generally accepted.8, 14  It is known that CQ accumulates in high concentrations 
in the plasmodium food vacuole via an ion trapping mechanism and inhibits 
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detoxification of heme.33  It is therefore believed that this acidic compartment is 
where the compound exerts its antimalarial effect.  A number of hypotheses have been 
raised to explain the mechanism of action of quinoline and related compounds.  It was 
demonstrated that the 4-aminoquinoline antimalarials were able to interact with both 
mammalian and malarial parasite DNA in vitro.34,35  It is thought that binding to the 
parasitic DNA prevents both RNA synthesis and DNA replication which leads to cell 
death. However, this does not explain the ability of CQ to kill parasites at 
concentrations much lower than the concentration at which it is toxic to mammalian 
cells.8  
 
Another hypothesis relating to its pharmacological activity is the inhibition of parasite 
feeding.  As the parasite matures within the host erythrocyte, it ingests small packets 
of haemoglobin by endocytosis.13, 36  These haemoglobin containing vesicles are 
transported to the parasite’s acidic food vacuole where the outer membrane of the 
double membrane is digested by a series of proteases. Ferriprotoporphyrin IX (FP) is 
freed during the breakdown of the haemoglobin.  CQ inhibits the biocrystallization of 
FP to haemozoin and also inhibits the normal degradation of accumulated FP by 
reduced glutathione.9, 37  Thus the changes seen shortly after the treatment of malarial 
parasites with pharmacological concentrations of the drug include swelling of the 
parasitic food vacuole and accumulation of undigested haemoglobin in the endocytic 
vesicles.12  CQ  is thought to act by selectively targeting the parasite and inhibiting the 
parasite specific process of haemoglobin degradation.8  CQ forms complexes with 
free FPIX which cannot be detoxified in the parasite by polymerization.13 
 
1.3.3 Pharmacokinetics of Chloroquine 
CQ is well absorbed orally, intramuscularly and subcutaneously in both healthy and 
diseased adults and children.38  It has a bioavailability of 70 to 80% when 
administered orally.39  Half time of absorption is 0.56 hours and peak plasma 
concentration is reached 1.5 to 3 hours after ingestion.  It is well distributed 
throughout the tissues and becomes concentrated in the infected erythrocytes.  CQ has 
also been shown to exist extensively in kidney, liver, spleen and lung tissue and is 
strongly bound to melanin containing cells.30  It has a very high apparent volume of 
distribution (between 100 and 1000 L/kg) and is 50 to 65% protein bound. CQ is 
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extensively metabolised by cytochrome P450 isoenzymes 2C8, 3A4 and 2D6 in the 
liver.38  The major metabolite desethylchloroquine retains the antimalarial activity of 
chloroquine.38, 40, 41  The major route of CQ excretion is by a relatively slow hepatic 
metabolism combined with renal excretion.  It is excreted very slowly; about 55% is 
excreted in the urine and 19% in the faeces.30  CQ has a long, highly variable half life 
between 8 and 58 days.  The long in vivo residual time of CQ is believed to lead to 
drug resistance.7, 9, 41  
 
1.3.4 Therapeutic Uses of Chloroquine 
CQ is taken both prophylactically and as a curative treatment for malaria.  For the 
treatment of an adult, 600 mg base is given followed by 300 mg base 6 hours later. 
The regimen is then 300 mg base per day at 24 and 48 hr.  In the treatment of a child, 
10 mg/kg base is given (maximum 600 mg). This is followed by 5 mg/kg base 6 hours 
later (maximum 300 mg) and 5mg/kg per day base at 24 and 48 hours.  For malarial 
prophylaxis in adults 300 mg base is given orally per week beginning one week 
before and continuing for 4 weeks after exposure.1 
 
1.3.5 Resistance to Chloroquine 
The most significant problem relating to CQ is parasitic drug resistance.  Its long half 
life and natural selection pressure on the parasite population has contributed 
significantly to CQ resistance.42, 43 CQ resistance is caused by increased drug efflux 
from the parasitic food vacuole or altered uptake rate.8  There are several potential 
explanations for the altered uptake rate, reflecting changes in the transmembrane pH 
in resistant parasites, altered membrane permeability characteristics, and, 
paradoxically, an efflux pump operating prior to cytosolic appearance of drug.  Two 
mdr like genes (multi drug resistant), pfmdr1 and pfmdr2 have been found in P. 
falciparum.8  Some evidence has suggested that mutations in pfmdr1 might be 
associated with resistance.8  CQ resistance can also be caused by reduced affinity of 
CQ for heme thereby reducing CQ uptake.  Initially CQ resistance was thought to be 
genetically attributed to cg2, a gene encoding for the polymorphic protein located at 
the periphery of the parasite.13  This mechanism may result in an increased drug efflux 
or decreased drug influx leading to a decrease in the accumulation of CQ in drug 
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resistant Plasmodium.43  However, this hypothesis has been ruled out by the 
transformation studies performed recently by Fidock et al.44  
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1.4 Piperaquine 
Piperaquine (PQ, Figure 9) is a bisquinoline antimalarial drug that was first 
synthesised independently by both the Shanghai Pharmaceutical Industry Research 
Institute in (China) and the Rhone Poulenc Company (France) in the late 1960s.45  It 
is effective against P. vivax and P. falciparum, including strains of P. falciparum 
resistant to chloroquine.  It is available as a free base and a tetraphosphate salt. 
Bisquinolines have been extensively studied in recent years because of their potent 
antimalarial activity against chloroquine resistant strains.2  
 
 
 
 
 
 
 
Figure 9 Chemical structure of Piperaquine 
 
1.4.1 Chemical Properties of Piperaquine 
Piperaquine (PQ) or 1, 3-bis [1-(7-chloro-4 quinolyl)-4-piperazinyl] propane (MW 
535.51) is a member of the 4-aminoquinoline group that includes CQ. PQ in the free 
base form is a pale white to yellow crystalline powder with a melting point of 212–
213°C.46,47  It is a hexabasic compound (pKa = 8.92) that is only sparingly soluble in 
water at neutral and alkaline pH, but has high lipid solubility (log P = 6.16).48  PQ is 
usually formulated as its water soluble tetraphosphate salt (MW 927.48)-a white to 
pale yellow crystalline power, freely soluble in water. It has a slightly bitter taste and 
a melting point of 246–252°C.2  The compound is known to be photosensitive in 
aqueous solution turning from yellow to deep orange on prolonged light exposure.2 
 
1.4.2 Mechanism of Action of Piperaquine 
Electron microscopy studies undertaken to study the effect of PQ on P. berghei 
ANKA strain have shown that the first morphological changes are swelling of the 
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food vacuole, vesiculation and accumulation of undigested haemoglobin.49  This 
suggests that the action of PQ involves blockage of the function of the food vacuole.  
CQ and bisquinolines such as PQ are weakly basic drugs and readily accumulate in 
the acidic parasitic food vacuole by several different mechanisms e.g. active transport 
and diffusion along a pH gradient.  When present in the food vacuole, CQ and the 
bisquinolines compete for the heme substrate. CQ has been shown to interact tightly 
with free heme and is known to induce premature termination of haemozoin polymers.  
Bisquinolines which are essentially two quinoline moieties linked together may 
chelate heme more efficiently and inhibit the catalase activity of heme to an even 
greater extent.50  The greater efficacy of the bisquinolines against CQ resistant 
parasites has been explained by the greater number of protonation sites compared with 
CQ which may allow these derivatives to be accumulated in higher concentrations 
within the CQ resistant parasites.13, 51  
 
1.4.3 Pharmacokinetics of Piperaquine 
The pharmacokinetic properties of PQ were only studied very recently despite its 
availability as a first line antimalarial agent in China for over three decades.  The first 
pharmacokinetic data for PQ in humans was published by Hung et al in 2004.52  They 
reported that the absorption of PQ was slow, with mean absorption half times of 9.1 
and 9.3 hours in adults and children, respectively. Slow absorption can likely be 
attributed to the high lipophilicity of PQ.  A more recent study by Davies and Illet at 
the University of Western Australia has shown the effects of food on absorption of 
PQ.52  They concluded that piperaquine absorption is increased in the presence of a 
high fat diet.53  They also established that the mean terminal elimination half-life was 
long in both adults (543 hours) and children (324 hours), whilst the mean volume of 
distribution at steady state/bioavailability (Vss/F) was very large in adults (574 L/kg) 
and children (614 L/kg).  Plasma protein binding of PQ has not been measured but is 
estimated to be around 97%.49   The metabolism of PQ in humans has not been studied 
in detail.  However, since PQ has no primary functional groups that could generate 
Phase 2 polar metabolites, it seems likely that a Phase I oxidative process occurring 
on either the quinoline or PQ ring structures may occur during its metabolism.2  
 
 17 
1.4.4 Therapeutic Uses Of Piperaquine 
PQ phosphate was first used for human antimalarial prophylaxis in China in 1978.2  
The standard clinical regimen dose employed was; 1.5–3.0 g PQ base given in divided 
doses over 2 or 3 days.  PQ was highly active against both chloroquine sensitive and 
chloroquine resistant species of P. falciparum.54  Due to fears related to the 
development of resistance and reports concerning cross-resistance between PQ and 
CQ, combination therapies with artemisinin derivatives were developed.  PQ based 
artemisinin combination therapy was developed in the form of CV8 in Vietnam, a 
formulation containing PQ, dihidroartemisinin, trimethoprim and primaquine.55  This 
combination has certain advantages over artesunate- mefloquine but has limited use 
because of lack of safety data in children and pregnancy.  A new combination of 
piperaquine ‘Artekin’ which contained dihidroartemisinin (DHA) and PQ phosphate 
was developed to reduce cost and toxicity.15, 56  Studies in children and adults in 
Cambodia showed very good activity and safety for this drug combination.56 
 
1.4.5 Resistance to Piperaquine 
Clinical studies have shown some degree of cross resistance between CQ and PQ.13, 57  
Resistance to PQ follows the same routes as CQ and is thought to have developed as a 
consequence of decreased drug accumulation.14  Processes changing the rate of influx 
of the drug such as changes in pH or a specific transport mechanism may decrease 
drug accumulation.58  Another mechanism is the active efflux of the drug from the 
food vacuole. Initially when bisquinolines such as PQ and hydroxypiperaquine (HPQ) 
were developed it was thought that their bulky structure would inhibit the efflux 
mechanisms developed by the parasite.14, 58   It has been suggested by Vennerstrom et 
al that the bulky structure may not be recognized by proteins involved in conferring 
quinoline resistance.50                      
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1.5 Hydroxypiperaquine 
Hydroxypiperaquine (HPQ, Fig 10) is a bisquinoline antimalarial drug first 
synthesized by the Chinese group led by Xu Dingqiu in 1971.3  HPQ displays very 
similar antimalarial activity to its parent compound PQ, both drugs show rapid and 
effective antimalarial activity.3 
 
 
 
 
 
 
Figure 10 Chemical structure of Hydroxypiperaquine 
 
1.5.1 Chemical Properties of Hydroxypiperaquine  
 HPQ base is a white or yellowish white crystalline powder, which is both odourless 
and tasteless. It has a melting point of 177-178.5°C. Its water soluble phosphate salt, 
HPQ phosphate is a pale yellow crystalline powder. It is also odourless, but with a 
slightly bitter taste and a melting point 237-238°C.3  
 
1.5.2 Mechanism of Action of Hydroxypiperaquine 
Chinese studies have shown HPQ to be highly effective schizonticide with rapid 
action against asexual stages of sensitive strains of P. falciparum and P. vivax.54  It 
has also been demonstrated that, HPQ displays very good activity against CQ resistant 
P. falciparum.54  The mechanism of action is believed to be similar to that of CQ and 
other bisquinolines although no formal studies have been undertaken.3, 8, 58, 59 In vitro 
studies have reported that HPQ displays more rapid action than PQ on P. berghei. 
However, its physiological effect on the parasitic fine structure was found to be 
similar to that of PQ.59 
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1.5.3 Pharmacokinetics of Hydroxypiperaquine 
Pharmacokinetic and pharmacodynamic studies of HPQ have not been published in 
the non-Chinese scientific literature.  All scientific and clinical data available on the 
drug has been published in Chinese scientific literature (mostly written in Chinese).  
Pharmacokinetic data is not available, but it is believed that HPQ unlike PQ would 
possess a shorter biological half life due to its additional hydroxyl group.  By virtue of 
this polar group, HPQ appears to be a prime candidate for Phase 2 metabolic 
conjugation processes e.g. glucuronidation and sulfation, which may significantly 
increase its biological clearance rate thus reducing its biological half life (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Phase 2 glucuronidation of HPQ 
 
 
 
1.5.4 Therapeutic Uses of Hydroxypiperaquine   
Initial reports on the clinical application of HPQ were reported in 1973, involving 
field studies undertaken in the South Western Yunnan province of China.3,60  Between 
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June and October 1973, 93 patients infected with acute P. falciparum malaria were 
treated with HPQ at a total dose of 1.5 g over three days. CQ phosphate at the same 
dose was given as a reference drug to some patients.  The study reported that the cure 
rate for hydroxypiperaquine was 98.33%.60 HPQ was more effective than CQ with a 
difference in fever and parasite clearance time which was statistically significant.60  
Its side-effects were few, and included somnolence, nausea and dizziness.  When 
compared to CQ the intensity of the side-effects experienced were milder.60  
Following this study, trials were performed with the drug against P. vivax malaria 
from 1974-1977 in the malaria endemic villages of Central China.57  Approximately 
700 patients infected with P. vivax malaria patients were treated with 1.2 g HPQ 
orally, (divided in two doses) and 350 reference patients were given oral chloroquine. 
However, results suggested no difference in mean parasite clearance time for both 
drugs.3,57  The toxicity observed with CQ, e.g. retinal toxicity, occurs largely because 
of its long-half life and high plasma concentrations.  It is known that the hydroxylated 
derivative of chloroquine, hydroxychloroquine is 2-3 times less toxic than the parent 
CQ.61   The introduction of a hydroxyl group into one of the N-ethyl groups of 
chloroquine gives hydroxychloroquine reduced toxicity by introducing a readily 
available functionality that could undergo glucuronidation leading to detoxification 
and more rapid excretion.61  A similar increase in the safety profile would be expected 
in HPQ due to its additional hydroxyl group.   
 
1.5.5 Resistance to Hydroxypiperaquine  
Initial in vitro studies on P. falciparum performed in China and Vietnam reported that 
HPQ showed cross resistance to CQ only at a very low level.3, 13 Clinical trials 
undertaken in Yunnan province (1975) showed HPQ cured the CQ resistant cases of P. 
falciparum malaria in the control wing.60  A similar trial was performed in Hainan 
Island were CQ resistant P. falciparum malaria is known to be common.  Confirmed 
CQ resistant cases were selected for treatment with HPQ and the study showed a cure 
rate of 90.62%.3  This is in contrast with several studies which have shown marked 
cross resistance between CQ and  bisquinolines.50,58,62,63  Experimental resistance 
models have been developed in China for resistance studies on chloroquine, 
piperaquine and HPQ.59  All three resistant lines developed in ANKA strains of P. 
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berghei exhibited a clear cross resistance to artesunate.59 Cross resistance between 
PQ/CQ and HPQ/CQ was not significant.59  
 
1.5.6 Synthesis of Hydroxypiperaquine     
The synthesis and chemical properties of HPQ have only been very briefly described 
in a review published by Xu et al in 1988.3  This review was published in an obscure 
medical research journal (Journal of Medical College of the People’s Liberation Army) 
and represents the only published synthetic work undertaken on the drug HPQ.  The 
review article briefly describes a three step scheme for the synthesis of HPQ (Figure 
12, reproduced from review published by Xu et al3).  Essential details such as molar 
ratios of the reactants, reaction conditions and solvents were not specified for any of 
these steps.  Brief details regarding the chromatographic (TLC and HPLC) and 
spectral (UV, IR, 1HNMR) analysis of HPQ are provided in a brief section but with 
virtually no information relating to the analytical procedures.  There have been no 
published reports on the reproducibility of this synthesis or the validity of the 
analytical data.  
 
 
Figure 12 Synthetic scheme for Hydroxypiperaquine (reproduced)3  
 
HPQ was synthesised by what appears to be at first glance a simple three step reaction 
process (Figure 12).  In the first step, piperazine was converted to its hydrochloride 
salt using hydrochloric acid.  In the second step, 1,3 dichloropropanol (1,3-DCP, the 
alkyl linker unit) was reacted with the piperazine salt to generate the bispiperazinyl-2-
hydroxypropane intermediate.  For the third and final step, 4,7- dichloroquinoline 
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(4,7-DCQ) was reacted with the bispiperazinyl intermediate in refluxing ethanol for 
20 hours.  Whilst the synthetic process appears to be uncomplicated and 
straightforward, previous attempts at reproducing this approach have failed in our 
laboratories.64  The most common problems encountered were the formation of the 
monosubstituted piperazinyl chloropropanol and the presence of inseparable starting 
materials-especially piperazine (in large quantities after the 2nd step). Both by-
products and starting materials were virtually impossible to remove from the reaction 
mixture in some instances, and in various steps resulted in low yields of unacceptable 
impure compounds.64  In addition, the method is difficult to monitor from a standard 
chromatographic standpoint e.g. TLC with UV detection, due to a lack of a 
chromophore in reactants and products in the first two synthetic steps. 
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1.6  Aim of the Research Project 
The primary aim of this project was to synthesise the antimalarial drug HPQ via 
alternative pathways to those described previously. The major objectives of the 
research program were to explore various synthetic strategies based on curent 
literature synthetic procedures involving similar compounds. The research was to 
explore various synthetic routes to generate the antimalarial compound HPQ – 
initially via methodology utilising N-monoprotected derivatives of piperazine.  To 
accomplish this, a range of N-monoprotected derivatives of piperazine was to be 
synthesised.  The N-monoprotected derivatives of piperazine were employed in turn to 
synthesize a range of N-monoprotected piperazine bis-adducts containing the 2-
hydroxypropane linker unit.  These bis-adducts should be easy to deprotect (i.e. 
remove the protecting group) using established literature methods. This deprotection 
step would be followed by a coupling reaction (catalysed by base) with 4,7-
dichloroquinoline (4,7-DCQ) to generate HPQ (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Proposed synthesis of HPQ using protected piperazine and 1,3-DCP 
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As an alternative approach, the synthesis of HPQ via the coupling of 4,7-DCQ and 
piperazine in the first step was to be considered (Figure 14).  Piperazine, upon 
reaction with 4,7-DCQ has two possible amino reactive sites, which can lead to the 
formation of an array of compounds e.g. unreacted piperazine, mono and disubstituted 
piperazinyl adducts.   To overcome this potential problem, suitably mono N-protected 
derivatives of piperazine could be utilised e.g. tertiarybutoxycarbonyl piperazine 
(tBOC-piperazine), benzylpiperazine and ethoxycarbonylpiperazine. These reagents, 
which already have one end of the piperazine molecule effectively blocked rendering 
it unreactive thus ensuring the reaction with 4,7-DCQ generates a single product 
namely a mono-N-protected piperazinyl quinoline.   This product should then be 
easily deprotected and reacted with a half molar equivalent of 1,3-DCP to yield HPQ. 
 
 
Figure 14 Proposed synthesis of HPQ using protected piperazine and 4,7-DCQ 
 
For a protecting group to find wide application in organic synthesis, it must fulfil 
several criteria.  In particular it must be selectively introduced into the molecule to be 
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during subsequent synthetic steps, including purification steps, until its deprotection is 
necessary. 65  It should be introduced and removed with the help of readily available 
reagents and should be easily purified.  Only a few protecting groups meet all of these 
demands, and in most cases a compromise must be found, in which the most 
important criteria are addressed.66  Benzyl groups can be commonly used for the 
protection of alcohols, carboxylic acids, amines, and diols.65  They can be removed 
under fairly mild conditions e.g. hydrogenolysis.  Ethoxy carbonyl group and tertiary 
butoxy carbonyl (tBOC) group are very commonly used in synthetic reactions to 
protect amines.  However, they are acid labile protecting groups and readily removed 
by acid-mediated hydrolysis using strong acids.65, 66  Among a number of protecting 
groups, tBOC is considered to be one of the most useful protecting groups. Its 
popularity is largely due to its ease of addition and removal.65  It has several 
advantages such as its stability to hydrolysis in basic conditions and inertness to many 
nucleophilic reagents.67  As stated above, reagents required for its removal must be 
acidic. A variety of reagents have been employed which include hydrochloric acid in 
ethyl acetate, sulphuric acid in dioxane, anhydrous hydrogen fluoride, boron 
trifluoride and trifluoroacetic acid.65  
 
1.6.1 Significance of the Research  
The research proposed, if successful, will be significant in many respects. Upon future 
publication this research will represent the only detailed synthetic procedure for the 
antimalarial HPQ.  In addition HPQ generated during this program will be 
biologically tested within the School of Pharmacy’s antimalarial research program 
(under the supervision of Dr Kevin Batty) to generate significant biological data 
regarding the compound.  This data will supplement research data acquired from the 
School of Pharmacy’s ongoing PQ research program. HPQ as an antimalarial has 
potentially numerous advantages over piperaquine.  The additional hydroxyl group in 
HPQ appears to make it a prime candidate for Phase 2 metabolic processes which 
should increase its clearance rate thus reducing its biological half life.  Theoretically 
the long half life of PQ is a major issue with regard to possible future malarial 
resistance thus diminishing the drug’s therapeutic use.  In addition to this, hydroxyl 
group present in HPQ should in theory be readily derivatized to afford a range of 
simple ester prodrugs.68, 69  Phosphate and succinate prodrugs of HPQ should 
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significantly increase the water solubility of the drug. The issue of low water 
solubility is a recognised problem with both HPQ and PQ. 
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2.1 General Details 
All reagents, starting materials and solvents were purchased from the Sigma-Aldrich 
Chemical Company, unless otherwise stated.  These materials were used without 
further purification. Solvents used were of laboratory grade and reactions were 
performed using QuickfitTM glassware.  Fume hoods were used when necessary, and 
stirrer heating mantles were employed for heating methods.  Propylene glycol oil 
baths were employed for the most part.  1H NMR (Nuclear Magnetic Resonance) 
spectroscopy was performed on a Varian Gemini 200 MHz spectrometer (School of 
Applied Chemistry, Curtin University of Technology).  Deuterated solvents including 
methanol (CD3OD), chloroform (CDCl3), dimethyl sulfoxide (DMSO-d6) and 
deuterium oxide (D2O) were employed as NMR solvents.  All chemical shifts (δ) are 
quoted in parts per million (ppm) and referenced against solvent peaks in the sample 
e.g. CHCl3 at δ7.27 for CDCl3.  Thin layer chromatography (TLC) analysis was 
performed on 20 × 20 cm precoated silica gel, aluminium backed plates, impregnated 
with a fluorescent indicator (254 nm).  A Spectroline model CM 10 florescence 
analysis cabin fitted with short and long wavelength UV lamps was used to view the 
TLC plates. Flash column chromatography was performed using silica as an adsorbent.  
Vacuum solvent evaporation was performed using a Buchi R-200 rotary evaporater.  
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2.1.1 Synthetic Approaches to the 1,3-(Bispiperazinyl)-propan-2-ol 
Intermediate using Mono-N-Protected Piperazine Derivatives 
 
The synthetic methods employed in attempts to prepare the intermediate 1,3-(bis 
piperazinyl)-propan-2-ol are described below.  The methodology is similar to that 
outlined in the initial stages of the synthetic process described by Xu et al. 3  However, 
our attempts would utilise mono-N-protected piperazine derivatives not piperazine.  
For the first step of our alternate approach, efforts were made to synthesize a range of 
N-mono protected piperazine derivatives.  These derivatives were to be used, in the 
second synthetic coupling step with 1,3-dichloropropanol (1,3-DCP) to generate     
1,3-(bis (N-protected)piperazinyl)-propan-2-ol. Subsequent deprotection of the 
protected adduct using a suitable acidic medium should yield the desired intermediate 
1,3-(bispiperazinyl)-propan-2-ol.  It was initially anticipated that the above approach 
would yield materials relatively free from impurities which would only require minor 
purification by recrystallisation. 
2.1.1.1 Synthesis of 1-benzylpiperazine dihydrochloride 70 
1-Benzylpiperazine dihydrochloride was synthesised in a two step reaction based on 
the method as described by Cymerman et al. 70 
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Figure 15 Synthesis of Piperazine Dihydrochloride salt 
 
To a solution of 12.521 g (2.50 mmol) of piperazine hexahydrate in 50 mL of absolute 
ethanol, 16.25 mL (161.2 mmol) of hydrochloric acid (10M) was added dropwise 
using a Pasteur pipette (10M HCl:  piperazine hexahydrate in the molar ratio of 1 : 
2.5).  The reaction flask was cooled in an ice bath to maintain a temperature of 25°C.  
After stirring for 20-30 minutes, the contents of the flask were cooled to about 0°C, 
and the crystalline white solid yielded was collected by vacuum filtration and washed 
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with two 25 mL portions of ice-cold absolute ethanol.  The identity of the solid was 
confirmed as piperazine dihydrochloride salt by 1H NMR spectroscopy (D2O).70  An 
ethanolic solution (50 mL) of piperazine hexahydrate (3.285 g, 0.65 mmol), was 
warmed to 65°C using a hot water bath.  To this solution, 3 g (0.51 mmol) of 
piperazine dihydrochloride was added with stirring.  The solution was vigorously 
stirred for 5 min during which time benzyl chloride (2.136 g, 0.25 mmol) was added 
via a Pasteur pipette.  
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Figure 16 Synthesis of 1-Benzylpiperazine 
 
The separation of white needles started almost immediately.  The solution was stirred 
for an additional 25 minutes at 65° C, and then cooled to room temperature.  The 
solution was allowed to stand in an ice bath for about 30 minutes.  Crystalline 
piperazine dihydrochloride monohydrate was collected by vacuum filtration.  The 
unreacted salt was washed with three 10ml portions of ice-cold absolute ethanol and 
dried.  The combined filtrate and washings from the piperazine dihydrochloride were 
cooled in an ice bath to 0°C and treated with 25 mL of absolute ethanol saturated with 
concentrated hydrochloric acid. After the solution was mixed, it was allowed to stand 
for 10-15 minutes in the ice bath.  The precipitated white plates formed were collected 
via suction filtration, washed with diethyl ether, and dried by rotary evaporation.  
TLC analysis and a 1H NMR spectrum (D2O) confirmed that the crystalline plates 
formed were the product required, 1-benzylpiperazine dihydrochloride. 
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2.1.1.2 Attempted Synthesis of 1-ethoxycarbonylpiperazine71-73 
 
1-Ethoxycarbonylpiperazine was attempted according to the method described by 
Krys’ko et al. 72 
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Figure 17 Synthesis of 1-ethoxycarbonylpiperazine 72 
 
An aqueous solution (50 mL) of 5 g piperazine hexahydrate (1 mmol) was acidified 
with acetic acid to pH 4–5 and cooled to 0°C.  To this solution was slowly added a 
solution of 15 mL (185 mmol) ethyl formate in 50 mL of isopropanol. The mixture 
was stirred for 2 h and diluted with water to 150 mL.  The excess of ethyl formate was 
extracted with two portions of 100 mL hexane.  The remaining aqueous solution was 
neutralized with aqueous NaHCO3 to pH 7, and an organic extraction was performed 
with chloroform.  The chloroform extracts were combined, washed sequentially twice 
with water (75 mL) and saturated NaCl (75 mL), then dried over anhydrous sodium 
sulphate (Na2SO4).  The drying agent was separated by filtration, and DCM 
evaporated to give a residue that was further dried in a vacuum oven to yield a golden 
brown oil.  However, TLC analysis of the oil showed multiple spots and comparison 
of 1H NMR spectral data from the literature source clearly showed that the reaction 
had failed to generate the desired product (mostly starting materials present). 
 
 
 
 
 
 
 
 
 
 
 32 
2.1.1.3 Attempted coupling reaction of 1-benzylpiperazine and 1,3-dichloropropanol 
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Figure 18 Synthesis of 1,3–bis(benzyl piperazinyl)propan–2-ol 
 
The product of the procedure 2.1.1.1, 1-benzylpiperazine dihydrochloride 498.366 mg 
(2 mmol) was dissolved in 20 mL of isopropanol.74  The solution was stirred with 691 
mg of K2CO3 (5 mmol) and 100 µL of 1,3-dichloropropanol (1 mmol).  The mixture 
was refluxed for 3 hr. TLC was performed at regular intervals but after 3 hrs the TLC 
analysis did not show any new spots for the product.  Therefore, the reaction was 
allowed to run for an additional 24 hrs.  TLC analysis after 24 hr showed a new 
compound spot. The reaction mixture was mixed with DCM (50 mL) and undissolved 
inorganic salts (e.g. K2CO3) were removed via filtration.  The filtrate obtained was 
evaporated to dryness using a rotary evaporater to remove all solvent (isopropanol and 
DCM).  However, 1H NMR spectrum (D2O) of the white solid obtained did not show 
the presence of the desired bispiperazinyl product required.  
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2.1.1.4 Attempted coupling reaction of tertiary butoxycarbonyl piperazine(t-BOC-
piperazine) and 1,3-dichloropropanol (1,3-DCP) in ethanol 
 
Cl Cl
OH
1,3-DICHLOROPROPANOL
(1,3-DCP)
∆/48 hr
N
H
N
O
tert-BUTOXYCARBONY
PIPERAZINE
(t-BOC PIPERAZINE)
K2CO3
N N
OHN N
t-BOC t-BOC
1,3-BIS(t-BOC PIPERAZINYL)-PROPAN-2-OL
O
EtOH
 
 
Figure 19 Synthesis of 1,3–Bis(tBOC-piperazinyl)propan 2-ol 
 
The method below describes an attempt to couple 1,3-dichloropropanol with 
commercially acquired tertiary butoxycarbonyl piperazine (tBOC piperazine). 
 
To a solution of 500 mg of tBOC piperazine (2.6 mmol) in 5 mL of absolute ethanol, 
371 mg of K2CO3 (2.6 mmol) and 128 µl of 1,3-dichloropropanol (1.3 mmol) were 
added with stirring.  The reaction mixture was stirred at reflux temperature for 24-48 
hr.74  TLC was performed at regular intervals using tBOC piperazine (in DCM) as a 
reference standard. TLC plates from 24 hour onwards showed multiple spots which 
were very close to each other and various mobile phase mixtures failed to separate the 
mixture further.74,75  The reaction mixture was suspended in DCM and filtered to 
remove K2CO3.  The filtrate obtained was evaporated to dryness to remove all 
solvents (ethanol and DCM) yielding a dark brown sticky solid. 1H NMR spectrum 
(CDCl3) showed peaks pertaining to the tBOC group and the formation of the product.  
However, coupled with the TLC analysis (showing multiple spots), it was evident that 
a complex mixture of compounds was present.  
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2.1.1.5 Attempted coupling reaction of tBOC piperazine and 1,3-dichloropropanol 
in  isopropanol. 
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Figure 20 Synthesis of 1,3-Bis(tBOC piperazinyl)propan-2-ol 
 
To a solution of, 500 mg of tBOC piperazine (2.6 mmol) in 10 mL of isopropanol, 
371 mg of K2CO3 (2.6 mmol) and 128 µl of 1,3-dichloropropanol (1.3 mmol) were 
added with stirring.  The reaction mixture was refluxed  for 24-48 hr.74  As in the 
previous attempt, the progress of the reaction was monitored by TLC. The same 
workup procedure was employed as for the previous attempt to yield a similar dark 
brown sticky solid.  1H NMR spectral analysis (CDCl3) of this solid yielded a similar 
spectrum to the previous attempt.  
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2.1.2 Approaches to the Synthesis of the 7-Chloro-4-(piperazine-1-yl) 
quinoline Intermediate using 4,7-Dichloroquinoline (4,7-DCQ) 
 
The approaches described in the previous section to synthesise 1,3-(bis piperazinyl)-
propan-2-ol via N-monoprotected derivatives of piperazine did not produce 
intermediates of satisfactory purity.  Hence an alternative approach for the synthesis 
of HPQ was embarked upon.  The following approach involved the synthesis of a               
7-chloro-4-(piperazine-1-yl)quinoline intermediate as described below (Figure 21). 
This intermediate does not possess a conventional protecting group but instead 
contains an essential building block for HPQ synthesis i.e. the 7-chloroquinoline unit.  
This unit also serves to block or protect one of the amino groups present in piperazine, 
thereby only permitting a coupling reaction at the remaining amino group.  The below 
coupling product could then be reacted with 1,3-DCP to give HPQ.63, 74, 76-81  The 
below intermediate, 7-chloro-4-(piperazine-1-yl)quinoline, can be synthesised  via 
two different synthetic methods.  Piperazine could be coupled with 4,7-DCQ in the 
presence of organic bases (e.g. triethylamine, diisopropylethylamine) or inorganic 
bases (e.g. K2CO3) to generate 7-chloro-4-(piperazine-1-yl)quinoline as described in 
Figure 21.  
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Figure 21 Coupling reaction of Piperazine and 4,7-DCQ 
 
 
Alternatively tBOC piperazine could be coupled with 4,7-DCQ in the presence of the 
above bases to generate 7-chloro-4-(tBOC-piperazine-1-yl) quinoline as described in 
Figure 22.  This compound on subsequent deprotection in a suitable acidic medium 
would yield 7-chloro-4-(piperazine-1-yl) quinoline. 
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Figure 22 Coupling reaction of Protected Piperazine and 4,7-DCQ 
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2.1.2.1 Attempted coupling reaction of 4,7- DCQ and piperazine in triethylamine 
base77, 82 
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Figure 23 Coupling reaction of 4,7-DCQ and Piperazine in triethylamine 
 
 
A solution of 500 mg of 4,7-dichloroquinoline (4,7-DCQ) (2.5 mmol) and 1.076 g  of 
piperazine (12.5 mmol) in 10 mL of triethylamine was heated for 48 hr at 80oC.  TLC 
analysis was performed at regular intervals (DCM: MeOH: Et3N 8.9:1:0.1 and DCM: 
Ethanol: Ammonia 100:8:1).  The reaction mixture was purified via flash column 
chromatography using silica and DCM: MeOH: Et3N (8.9:1:0.1) as the mobile 
phase.83-85 The product fractions obtained were concentrated using a rotary evaporater 
and analysed via 1H NMR spectroscopy (CDCl3).  The 1H NMR spectrum of the dark 
brown resinous solid obtained showed peaks for the presence of trace amounts of 4,7-
DCQ (starting material) and impurities such as ethanol, water and silicone grease. 
There were no peaks for the formation of the product.  
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2.1.2.2 Attempted coupling reaction of 4,7-DCQ and piperazine in triethylamine 
and N-methyl pyrrolidinone bases 77, 82 
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Figure 24 Coupling reaction of 4,7-DCQ and piperazine in triethylamine and   N-
methyl pyrrolidinone 
 
In a mixture of Et3N (3 mL) and N-methyl pyrrolidinone (NMP,7 mL), 500 mg of 4,7-
DCQ (2.5 mmol) and 1.076 g of  piperazine (12.5 mmol) was dissolved and heated for 
48 hr at 80oC. TLC was performed at regular intervals (DCM: Ethanol: Ammonia in 
the ratio 100:8:1).  A solution of 4,7-DCQ in DCM was used as the reference spot to 
assess the progress of the reaction.  TLC analysis after 48 hours showed the presence 
of new spots and the reaction mixture was extracted and purified via a basic work up.  
The work up procedure included extraction with three 50 mL portions of 10% NaOH 
solution and subsequently with three 50 mL portions of saturated NaCl solution.  The 
organic phase was dried using 10 g of sodium sulphate, filtered and concentrated 
using a rotary evaporator.  A shiny chocolate coloured solid free from solvent was 
obtained. Spectral analysis of the solid was performed by 1H NMR (CDCl3), but did 
not show peaks for the desired product (only NMP was present).   
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2.1.2.3 Attempted coupling of 4,7-DCQ and piperazine with catalytic amounts of 
KI  78, 82 
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Figure 25 Attempted coupling of 4,7-DCQ and piperazine with catalytic amounts 
of KI 
 
A solution of 1.980 g of 4,7-DCQ (10 mmol), 4.307 g of piperazine (50 mmol) and 
100 mg of  KI in 20 mL of diisopropyl ethylamine (DIPEA, Hunig’s base) was heated 
for 48 hr at 80°C.  TLC was performed at regular intervals (DCM: Ethanol: Ammonia 
100:8:1). After 48 hr the reaction mixture was extracted via a basic work up.83, 85  A 
shiny chocolate coloured solid free from solvent was obtained. However, the 1H NMR 
spectrum (CDCl3) of the solid showed peaks for 4,7-DCQ only. 
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2.1.2.4 Attempted coupling reaction of 4,7-DCQ and piperazine 
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Figure 26 Coupling reaction of 4,7-DCQ and piperazine 
 
A mixture of 10.8 g of piperazine (125.37 mmol), 1.047 g of K2CO3(7.58 mmol), 5.28 
mL of triethylamine (37.98 mmol) and 5.00 g of 4,7-DCQ (25.25 mmol) was stirred 
in 17.7 mL of NMP at 135°C for 2h.  TLC analysis was performed at 1 hour interval 
(DCM: Ethanol: Ammonia 100:8:1).  After cooling to room temperature the reaction 
mixture was diluted with 200 mL DCM.   The reaction mixture was washed twice 
with 50 mL brine, dried with MgSO4 and concentrated using a rotary evaporater. 83, 85  
The resulting yellow oil was purified by column chromatography on silica using 
CH2Cl2/ MeOH (4:1) as the eluent. The fractions containing the product were 
concentrated using rotary evaporater to give a pale yellow oil which was analysed by 
1H NMR spectroscopy (CDCl3).  However, the 1 H NMR spectrum given showed no 
product peaks and the presence of piperazine only.  
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2.1.2.5 Attempted coupling reaction of 4,7-DCQ and tBOC-piperazine in 
diisopropyl ethylamine base78, 82 
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Figure 27 Coupling reaction of 4,7-DCQ and tBOC-piperazine in         
diisopropyl ethylamine (DIPEA) 
 
A solution of 1 g of 4,7-DCQ (5 mmol) and 1 g of tBOC-piperazine (5 mmol) in 10 
mL of DIPEA was heated for 48 hr at 800 C.    The TLC (DCM: Ethanol: Ammonia 
100:8:1) performed on the reaction mixture showed the formation of new compounds. 
The reaction mixture was worked up with 10% NaOH and saturated NaCl.83, 85  The 
organic phase obtained was dried and concentrated as in the previous attempt (see 
page 40). A shiny chocolate coloured solid free from solvent was obtained.  Flash 
column chromatography purification was performed with DCM: Ethanol: Ammonia 
200:8:1 as the eluent solvent mixture.  Combined fractions with expected spots 
pertaining to the product were dried using a rotary evaporator.  The 1H NMR 
spectrum (CDCl3) of the shiny chocolate coloured solid obtained showed peaks for 
the formation of the product but also displayed peaks pertaining to starting materials 
i.e. 4,7-DCQ, tBOC-piperazine and DIPEA (minute quantities of DCM solvent were 
also evident). 
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2.1.2.6 Coupling reaction of 4,7-DCQ and tBOC-piperazine in DIPEA with 
catalytic amounts of KI78, 82 
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Figure 28 Coupling reaction of 4,7-DCQ and tBOC-piperazine in         
diisopropyl ethylamine with catalytic amounts of KI 
 
A solution of 1.980 g of 4,7-DCQ (10 mmol), 1.86 g of tBOC-piperazine (10 mmol) 
and 100 mg of KI in 20 mL of DIPEA was heated for  48 hr at 80°C. TLC analysis 
was performed at regular intervals (DCM: Ethanol: Ammonia 100:8:1). The mixture 
was purified via basic work up as in the previous reactions.   A shiny chocolate 
coloured solid (free from solvent) was obtained.  Flash column chromatography 
purification was performed with DCM: Ethanol: Ammonia 200:8:1 as the eluent 
solvent mixture.  The 1H NMR spectrum (CDCl3) of the chocolate coloured solid 
given showed peaks for the intermediate 7-chloro-4-(tBOC-piperazine-1-yl)quinoline. 
The amount of product obtained was 1.610 g. Based on 10 mmol of 4,7-DCQ and 
tBOC piperazine utilised the reaction yield was 46%. The product was relatively free 
from impurities such as solvent and starting material apart from minute quantities of 
tBOC piperazine, which could be seen from the integration of the 9H singlet (tBOC) 
at δ 1.50 ppm; this is probably due to spinning side bonds.  There also where two 
small multiplets at δ 3.00 and δ 3.60 ppm which could be attributed to the tBOC 
piperazine starting material. 1H NMR (200MHz, CDCl3) δ ppm 1.50 (singlet, 9H, 
tBOC), 3.43 (multiplet, 4H, 2 H-21& 61) , 3.72 (doublet, 4H, 2 H-51& 31), 6.95 
(doublet, 1H, H-3), 7.50 (doublet of doublets, 1H, H-6), 7.94 (doublet, 1H, H-5), 8.40 
(doublet, 1H, H-8), 8.61 (doublet, 1H, H-2). 
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2.1.2.7 Deprotection of the tBOC coupling product, 7-chloro-4-(tBOC piperazine-
1-yl) quinoline.87, 88 
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Figure 29 Synthesis of 7-chloro-4-(piperazine-1-yl)quinoline 
 
Deprotection of the coupling product from the last procedure was performed to 
remove the tertiary butoxycarbonyl (tBOC) group and render the secondary amino site 
free for reaction with 1,3- dichloropropanol for the final synthesis of HPQ.  
 
The products from the reactions described in Sections 2.1.2.5 (730 mg) and 2.1.2.6 
(3.0 g) were placed into two separate 100 mL round bottom flasks.  To each flask, 
50% TFA: DCM (10 mL of TFA and 10 mL of DCM) were added and stirred for 15 
mins at room temperature.  By-products and excess TFA were removed via the 
following basic workup procedure. Contents of both the flasks were combined and the 
product mixture was made alkaline using sodium bicarbonate and then washed with 
50 mL 10% NaOH and 50 mL saturated brine.83, 85  The organic phase was separated 
and dried using MgSO4.  Upon concentration in a rotary evaporator, a pale brown 
coloured solid (1.720g) was obtained. The reaction yield was 64.7% based on the 
combined mass of the starting materials. 1H NMR spectra (CDCl3) of the solids were 
obtained and compared to the literature data.76, 77 The spectrum correlated with the 
peaks specified in the literature and showed the presence of the desired deprotected 
product. 1H NMR (200MHz, CDCl3) δ ppm 2.18 (singlet, 1H, H-41), 3.43 (singlet, 8H, 
2 H-51& 31 and 2 H-21& 61) , 6.95 (doublet, 1H, H-3), 7.50 (doublet of doublets, 1H, 
H-6), 7.94 (doublet, 1H, H-5), 8.40 (doublet, 1H, H-8), 8.61 (doublet, 1H, H-2).  
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2.1.3 Synthesis of Hydroxypiperaquine (HPQ) 
2.1.3.1 Synthesis of HPQ using an organic base 77, 82 
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Figure 30 Synthesis of HPQ using an organic base 
 
In a solvent and base mixture of 2 mL of DIPEA, 5 mL of TEA and 2 mL of NMP, 
248 mg of 7-Chloro-4-(piperazin-1-yl)quinoline (1 mmol) and 50 µl of 1,3-
dichloropropanol were dissolved.  10 mg of KI was added (as a catalyst) and the 
reaction mixture was continuously refluxed for 24 hr.  TLC was performed in DCM: 
Ethanol: Ammonia (100:8:1) and a DCM solution of 7-chloro-4-(piperazin-1-
yl)quinoline was used as a reference to assess the reaction progress.  TLC after 24 hr 
showed a new spot therefore the reaction mixture was purified via a basic work up as 
described in previous sections (see Page 40).  The pale chocolate coloured solid 
obtained was analysed by 1H NMR spectroscopy (CDCl3).  However, the spectrum 
clearly showed that the desired product (HPQ) was not present. Impurities like 
solvents (NMP and DCM) and starting material (1,3-DCP) were present. 
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2.1.3.2 Synthesis of HPQ using an inorganic base in isopropanol 63, 82 
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Figure 31 Synthesis of HPQ using an inorganic base 
 
To a solution of 500 mg of 7-chloro-4-(piperazin-1-yl)quinoline (2.5 mmol) and 128 
µl of 1,3-dichloropropanol (1.3 mmol) in 10 mL of isopropanol, 370 mg of K2CO3 
(2.7 mmol) and 100 mg of KI were added.  The mixture was stirred at reflux for 48 h.  
TLC was performed in DCM: Ethanol: Ammonia 100:8:1.  The reaction mixture was 
purified via a basic workup as described in the previous reactions (see Page 40) to 
yield a pale chocolate coloured solid.  As for the latter attempt, (from the 1H NMR 
spectrum) there appeared to be no HPQ present in the solid. (Peaks observed for 
chloroform and water only).  
 
 
 
2 
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2.1.3.3 Synthesis of HPQ  from 7- chloro-4-(piperazin-1-yl) quinoline using 
inorganic base in ethanol 63 
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Figure 32 Synthesis of HPQ from 7-chloro-4-(piperazin-1-yl)quinoline using 
Na2CO3 
 
 
A mixture of 248 mg of 7-chloro-4-(piperazin-1-yl)quinoline (1 mmol) and 50 µL of 
1,3-dichloropropanol (0.5 mmol) were stirred in 1 mL of ethanol.  To this was added 
with stirring 52.5 mg (0.5 mmol) of Na2CO3.  The mixture was stirred at room 
temperature for 5 hr.  To workup the solution, 15 mL of DCM was added and the 
solution was subsequently dried over Na2SO4.  After filtration the solvent was 
removed by rotary evaporation yielding a dark brown oily liquid.  The oil present was 
analysed by 1H NMR spectroscopy (CDCl3). As for both previous attempts, the 
spectrum obtained showed no peaks pertaining to HPQ (only 1,3-DCP was present). 
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2.1.3.4 Synthesis of HPQ using an inorganic base in amyl alcohol 
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Figure 33 Synthesis of HPQ using an inorganic base in amyl alcohol 
 
To a stirring solution of 0.992g of 7-chloro-4-(piperazin-1-yl)quinoline (4 mmol) in 
10 mL of amyl alcohol (1-pentanol), 0.660 g of K2CO3 was added.  To this solution, 
200 µL of 1,3-dichloropropan-2-ol (2.1 mmol) was added using a Pasteur pipette.  
The solution was heated at a temperature of 120°C overnight (14 hours).  After 14 
hours, a dark solid material suspended in a clear pale yellow solution was produced.  
The material was extracted and purified via a basic work up as described in previous 
sections (see Page 40).  A shiny chocolate coloured solid free from any solvent was 
obtained after the workup.  TLC analysis on this compound showed considerable 
amounts of impurities and the starting material. Flash column chromatography was 
undertaken to purify the solid using an eluent of gradually increasing polarity starting 
with 200:8:1 DCM: Ethanol: Ammonia.   The fractions containing the suspected 
product were concentrated using rotary evaporater to give a brownish yellow coloured 
solid (683mg). Based on the ratio, 2 mmol of 7-chloro-4-(piperazin-1-yl)quinoline 
and 1mmol of 1,3-DCP produce 1mmol of HPQ the reaction yield for 2 mmol of HPQ 
was 59.0% (with solvent impurities).   The 1H NMR spectrum of the solid obtained 
showed peaks for the aromatic part of  HPQ consistent with the reference spectral data 
2 
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for HPQ as described by Xu et al 3. A few trace impurities such as amyl alcohol seen 
in the non-aromatic region and DCM were present. 1H NMR (200MHz, CDCl3) δ ppm 
2.30 (Doublet, 4H, CH2-propanol × 2), 2.80 (Singlet, 8H, 2H-51 and 2H-31piperazine× 
2), 3.40 (Broad singlet, 8H, 2H-21 and 2H-61piperazine × 2), 3.60 (Broad singlet, 1H, 
OH), 4.10 (Pentet, 1H, CHOH), 6.88 (Doublet, 2H, H-3 × 2), 7.49 (Doublet of 
doublets, 2H, H-6 × 2), 7.97 (Doublet, 2H, H-5 × 2), 8.10 (Doublet, 2H, H-8 × 2), 
8.71 (Doublet, 2H, H-2 × 2). 
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3  RESULTS & 
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3.1 Outline of the Synthetic Approaches to HPQ 
3.1.1 HPQ synthesis described by Xu et al 3 
Whilst numerous journal articles and reports have addressed its antimalarial efficacy 
and clinical uses of hydroxypiperaquine (HPQ), the literature regarding its synthesis is 
virtually non-existent.  The sole exception to this is the review published nearly 20 
years ago by Xu et al in the Journal of the Medical  College of the People’s Liberation 
Army (JMCPLA).3  The review contains the only published synthetic work relating to 
HPQ but there have been no subsequent reports on its efficiency, reliability and 
reproducibility.  
 
 The synthesis and chemical properties of HPQ were first described very briefly in the 
above review by Xu et al.3  They synthesised HPQ via a simple four step reaction 
procedure.  However, the review does not include any specific experimental details 
pertaining to the synthetic procedure and the only information relating to the synthesis 
is in the form of a diagrammatic reaction scheme shown below (Figure 34). 
 
 
 
Figure 34 Reproduced scheme for the synthesis of HPQ described by Xu et al 3 
 
In the first step of the synthetic procedure, piperazine was converted to its 
hydrochloride salt using hydrochloric acid (HCl) but no solvent was specified.  For 
the second step, 1,3-dichloropropanol (1,3-DCP) was reacted with the above 
piperazine salt.  A reaction temperature of 110-120°C was specified and the reaction 
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was carried out for 3 hours yielding 1,3-bis-(piperazinyl)-propan-2-ol (70% yield). 
Oddly, no solvent is specified for this second step. In the third step, 4,7-
dichloroquinoline (4,7-DCQ) was coupled with the above bispiperazinyl product by 
refluxing in ethanol for 20 hours to give HPQ (80% yield).  Whilst this approach 
appeared straightforward, previous attempts at reproducing the synthesis in our 
laboratory were unsuccessful.64  The lack of experimental details and conditions for 
all the steps significantly hampered its reproduction.  In particular, important 
information relating to the amounts of reagents and reaction solvents for each step 
were not provided.  In earlier efforts to reproduce the synthesis, the reaction 
conditions were varied (in particular relative amounts of reactants) and numerous 
problems were encountered.64  The most common problems encountered were the 
formation of monosubstituted piperazinyl chloropropanol and the presence of starting 
materials (especially piperazine) in very large quantities.  Both by-products and 
unreacted starting materials proved very difficult to remove from the reaction mixture 
via conventional means resulting in low and unacceptable yields of products at best 
(at worst crude and pharmaceutically unacceptable product mixtures).  In addition, 
rapid analytical monitoring of the first two steps of the process was particularly 
difficult as both piperazine and 1,3-DCP lack an effective chromophore, making TLC 
plates difficult to visualise using conventional UV detection. TLC analysis previously 
performed using various stains for plate visualisation and compound detection (e.g. 
anisaldehyde, iodine and potassium permanganate) met with very little success. 
 
3.1.2 Summary of synthetic approaches 
The present research explored various synthetic strategies to synthesize HPQ in an 
efficient manner.  The starting compound, piperazine is dibasic and contains two 
secondary amino groups both of which have the same susceptibility to nucleophilic 
substitution reactions using alkyldichlorides. Reaction of piperazine via this process 
can lead to the formation of an array of alkylated compounds - namely 
monosubstituted and disubstituted products (and depending on the conditions possibly 
unreacted piperazine).  To overcome this issue, previous attempts at the synthesis 
utilised an excess of piperazine where in fact piperazine acts as both reactant and base 
catalyst for the substitution reaction.  It has been demonstrated by many studies that 
base catalysts increase nucleophilicity of amino compounds via amino group 
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deprotonation.89  An alternative approach which may limit the amount of bis by–
products is to utilise mono-N-protected derivatives of piperazine.  It was intended in 
our initial proposal to synthesize or possibly commercially acquire a selection of these 
protected derivatives namely tertiary butoxy carbonyl piperazine (tBOC piperazine), 
1-benzylpiperazine and 1-ethoxycarbonylpiperazine.  Most of these protecting groups 
have a UV chromophore which would assist in the monitoring of the reactions by 
TLC with UV detection. Also, a protected piperazine should in theory react more 
cleanly with the alkyl dichloride (1,3-DCP), at the unprotected amino group as it 
would be the only site available for  nucleophilic attack.  The protected product 
generated on subsequent removal of the protecting group should provide the desired 
intermediate, 1,3-bis-(piperazinyl)-propan-2-ol, which could then be coupled with two 
molar equivalents of 4,7-DCQ to provide HPQ (Figure 35). 
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Figure 35 Proposed synthesis of Bis-(protected piperazinyl)propan-2-ol 
 
In addition to the above, a second alternative synthetic approach to HPQ is possible, 
involving the direct coupling reaction of 4,7-DCQ and either piperazine or an N-
monoprotected piperazine derivative. This would generate one of the two 
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intermediates, 7-chloro-4-(piperazin-1-yl)quinoline (Figure 36) or 7-chloro-4-(N-
monoprotected piperazin-1-yl)quinoline (Figure 37).  Both intermediates could 
subsequently be reacted with 1,3-DCP to afford HPQ.  
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Figure 36 Proposed synthesis of 7-Chloro-4-(piperazin-1-yl)quinoline 
 
N
H
N
PG
REFLUX
SOLVENT
MONOPROTECTED
PIPERAZINE
NCl
Cl
4,7-DICHLOROQUINOLINE
(4,7-DCQ)
BASE
PG
NCl
N
N
7-CHLORO-4-MONOPROTECTED
PIPERAZINYL QUINOLINE ADDUCTPG = PROTECTING GROUP
COUPLING
STEP
 
 
Figure 37 Proposed synthesis of 7-Chloro-4-(protected piperazin-1-yl)quinoline 
 
All starting materials, intermediates and products generated via this approach would 
posses a chromophore and hence the above reactions should be easily monitored via 
conventional TLC with UV detection.  A literature review revealed that three different 
methods have been previously published to synthesise 7-chloro-4-[piperazin-1-
yl]quinoline.  The first literature method by Vennerstrom described the synthesis of 
novel bisquinolines and synthesized 7-chloro-4-[piperazin-1-yl]quinoline by reaction 
of 4,7-DCQ and piperazine in a molar ratio of 1:10.63  The reactants were refluxed 
under argon atmosphere for 24 hours in 2-ethoxyethanol solvent.  They showed that 
by simply cooling and reheating the reaction mixture the excess unreacted piperazine 
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could be distilled off.  The second approach by Chiyanzu et al described the synthesis 
of 4-aminoquinoline isatin derivatives.76 7-chloro-4-[piperazin-1-yl]quinoline was 
synthesized as an intermediate by reacting 4,7-DCQ and piperazine in a 1:5 molar 
ratio.   They used both inorganic (K2CO3) and organic bases (triethylamine) as 
catalysts in N-methyl-2-pyrrolidinone solvent.  The preparation of 7-chloro-4-
[piperazin-1-yl]quinoline was carried out at 135°C for 4 hours under a nitrogen 
atmosphere. The third method described by Clarkson et al coupled 4, 7-DCQ with 
piperazine in a 1:5 molar ratio in the presence of both K2CO3 and triethylamine  under 
nitrogen at 135ºC for 2 hours in N-methyl-2-pyrrolidinone.77  It was our intention to 
repeat the latter method (see section 3.3.1) as all the reagents used in this method were 
available in our laboratory and the reaction conditions were easily reproducible. 
However, the reported product yield of 87.5 % was the major reason why this method 
was attempted.  
 
3.2 Synthetic Approaches to HPQ using N-Mono Protected 
Piperazine Derivatives 
 
Three methods using N-mono protected derivatives of piperazine were to be attempted.  
• Coupling of 1-benzylpiperazine with 1,3-dichloropropanol to synthesise bis 
(benzyl)piperazinyl-propan-2-ol. 
• Coupling of tBOC-piperazine with 1,3-dichloropropanol to synthesise bis 
(tBOC)piperazinyl-propan-2-ol. 
• Coupling of 1-ethoxycarbonylpiperazine with 1,3-dichloropropanol to 
synthesise bis(ethoxycarbonyl)piperazinyl-propan-2-ol. 
Each bis-adduct should be easily deprotected and subsequently coupled with two 
molar equivalents of 4,7-DCQ to provide HPQ.  Whilst, tBOC piperazine is a 
commercially available compound from the Sigma-Aldrich Chemical Company,       
1-benzylpiperazine and 1-ethoxycarbonylpiperazine were synthesized in our 
laboratory according to recent literature methods.70, 72    
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3.2.1 Synthesis of 1-Benzylpiperazine Dihydrochloride 
1-Benzylpiperazine dihydrochloride was synthesised according to the literature 
method of Cymerman et al (see page 29).70  This method involved the synthesis of              
1-benzylpiperazine via a two step process.  The first step involved the synthesis of 
piperazine dihydrochloride monohydrate.  This in turn was reacted in the second step 
with benzyl chloride in the presence of piperazine hexahydrate (organic base catalyst 
and assists in reagent solvation) to afford 1-benzylpiperazine dihydrochloride. The 
methods described were facile, in comparison to an alternative method described by 
Bergbreiter et al using 1-ethoxycarbonylpiperazine.90  By following Cymerman 
method, 1-benzylpiperazine dihydrochloride was successfully quantitatively 
synthesised.70  
 
3.2.2 Synthesis of 1-Ethoxycarbonylpiperazine 
The method used to synthesise 1-ethoxycarbonylpiperazine was based on a synthetic 
method published by Krys’ko et al, (see page 31).72  They describe the synthesis of    
1-ethoxycarbonylpiperazine by the reaction of an aqueous solution of piperazine with 
ethyl formate in isopropanol.72 Alternative literature methods included the reaction of 
piperazine with ethyl chloroformate in xylene described by Kushner et al.73  After 
careful scrutiny of the methods available the Krys’ko method appeared to be simpler, 
because of the ready availability of all reagents involved. 
 
However, attempts to reproduce the above synthesis were not successful. Upon closer 
examination of the research article a typographical error was noted in the 
experimental section relating to the reactants employed. Ethyl formate was specified 
in this section but the accompanying reaction scheme featured ethyl chloroformate. 
Clearly the latter reagent should have been employed in the synthesis of the               
1-ethoxycarbonyl piperazine. Further attempts to synthesize ethoxycarbonylpiperazine 
were not pursued because two alternative protected piperazines were now available to 
us - namely 1-benzylpiperazine and commercially available tBOC piperazine. Time 
constraints and reagent unavailability did not permit us to reattempt the above 
synthesis with ethyl chloroformate.  In addition, other errors in the paper relating to 
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the use of incorrect molecular weights and molar amounts of reagents were also noted 
upon further examination. 
 
3.2.3 Coupling reaction of Protected piperazine and                        
1,3-Dichloropropanol  
Three methods for the coupling of 1,3-dichloropropanol with N-protected piperazine 
were attempted.  The first involved the coupling of 1-benzylpiperazine with                    
1,3-dichloropropanol (see page 32).  The second and the third methods involved the 
attempted coupling of tBOC-piperazine with 1,3-dichloropropanol in two different 
solvents (see pages 33 and 34).  The coupling of 1-benzylpiperazine with                
1,3-dichloropropanol was attempted using isopropanol as a solvent.  Isopropanol was 
selected because of results from a solubility assessment performed by Fong. 64 This 
earlier work performed in our laboratory showed that both starting materials                
(1-benzylpiperazine and 1,3-dichloropropanol) were very soluble in low molecular 
weight alcohols such as methanol, isopropanol and ethanol. High molecular weight 
alcohols e.g. amyl alcohol were not used inspite of their higher boiling points as they 
showed poor solubility for the reactants.64 It was speculated that the use of a higher 
boiling point solvent (isopropanol), allowing a higher reflux temperature, would 
improve the reaction yield.  Potassium carbonate (K2CO3) was used as a catalytic base 
in all of the three coupling methods attempted.  The use of K2CO3 as an inorganic 
base in nucleophilic substitution reactions has been described by various research 
groups.74,76,77,91  This inorganic base can be used in a variety of organic solvents. Both 
Clarkson and Chiyanzu et al described the use of K2CO3 in N-methyl-2-pyrrolidinone 
as a solvent.76, 77 They have also used an organic base, triethylamine, in combination 
with K2CO3.  It has also been used in dimethyl formamide (DMF) by Ryckebusch et 
al.92  Kumar et al have described the use of K2CO3 for the synthesis of 
hydroxychloroquine in the absence of any solvent.82  We decided to attempt the 
coupling of 1-benzylpiperazine with 1,3-dichloropropanol under continuous reflux 
conditions for 3 hr using K2CO3 in iPrOH. (see Figure 18, Page 32). 
 
 
However, the TLC analysis of the reaction mixture after 3 hours did not show any 
new compound spots for a product, therefore the reaction was continued for 24 hours. 
Further TLC analysis showed multiple spots after 24 hours. However, 1H NMR 
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spectral analysis of the reaction mixture following workup did not indicate the 
presence of the desired product.  
 
The second method attempted the coupling reaction of tBOC-piperazine with 1,3-
dichloropropanol (see Figure 19, Page 33).  The conditions employed for this reaction 
were similar to the previous coupling reaction except for the use of ethanol as the 
solvent.  Again the selection of solvent was primarily based on its boiling point and its 
ability to dissolve tBOC piperazine. However, a mixture of compounds was found to 
be present on 1H NMR spectral analysis of the brown solid obtained.   
 
The final method attempted was similar to the latter approach but involved the 
coupling of 1,3-dichloropropanol with tBOC-piperazine in isopropanol (see Figure 20, 
Page 35). The reaction conditions were the same as the previous two reactions i.e. the 
reaction was carried out at reflux for 48 hours. However, TLC analysis of the reaction 
showed various spots which could not be separated even with various combinations of 
mobile phase mixtures e.g. DCM: ethanol: ammonia, DCM: methanol: triethylamine 
and petroleum ether: ethyl acetate.   
 
The failure of all the above methods suggested that aprotic solvents such as 
dimethylformamide, acetone or acetonitrile would have possibly been more suitable 
for these reactions. The above reactions are probably operating via a substitution 
nucleophilic bimolecular (SN2) mechanism. It has been observed that polar aprotic 
solvents can increase the rate of such reactions by up to 109 fold (by increasing the 
reactivity of the nucleophile).  The nucleophile under aprotic conditions is not 
surrounded by a shell of solvent molecule (a nucleophilic solvation envelope) unlike 
in the presence of protic solvents (e.g. methanol) where its nucleophilicity is 
diminished due to hydrogen bonding with the solvent.93  Previous attempts in our 
laboratory involving the use of aprotic solvents have been problematic. The use of 
dimethyl formamide (DMF) has met with some success but difficulties have arisen in 
relation to the removal of this high boiling point solvent via conventional rotary 
evaporation.64  Due to time constraints, this solvent and other aprotic solvents such as 
acetone, tetrahydrofuran, dimethyl sulfoxide and dioxane were not trialled       
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3.3 Synthetic Approaches to 7-Chloro-4-(piperazin-1-yl) 
quinoline Using 4,7-Dichloroquinoline 
 
Two synthetic approaches were attempted to synthesise the above intermediate                
7-chloro-4-(piperazin-1-yl)quinoline.  The first approach was a direct method which 
involved the coupling of 4,7-DCQ with piperazine in the presence of either inorganic 
base or organic bases.  The second approach involved the coupling of 4,7-DCQ with 
tBOC protected piperazine to give 7-chloro-4-(tBOC piperazin-1-yl)quinoline.  On 
subsequent deprotection with trifluoroacetic acid (TFA) this product would provide                               
7-chloro-4-(piperazin-1-yl)quinoline.  Numerous methods have been published 
relating to the synthesis of similar compounds by the coupling of 4,7-DCQ with a 
variety of primary, secondary or diamino compounds.  The solvents, bases and 
reaction conditions employed in these published reactions will be discussed in the 
sections below. 
 
3.3.1 Attempted Coupling of 4,7-DCQ and Piperazine 
Four different methods for the coupling reaction of 4,7-DCQ and piperazine utilizing 
a variety of solvents and bases were attempted (see pages 35-40).  The first method 
involved the coupling of 4,7-DCQ with piperazine using triethylamine as an organic 
base (see page 37).  The reaction was carried out by heating the reactants at a 
temperature of 80ºC for 48 hours. This approach was based on similar synthetic 
procedures.76-78, 81, 82, 91  Triethylamine has been employed as a base by Kumar et al in 
the synthesis of hydroxychloroquine.82  The use of this base has been further cited in 
methods described by Clarkson et al77, Beagley et al80 and Chiyanzu et al.76 Kumar 
emphasized the use of organic bases such as triethylamine, diisopropylethylamine in 
the absence of any solvents i.e. the base functions as both catalyst and solvent.82  
Other published methods employed organic bases in solvents such as N-methyl-2-
pyrrolidinone, isopropanol and ethanol.50, 63, 76, 77, 91  The role of base in nucleophilic 
aromatic substitution reactions can be critical to the success of these reactions.  The 
above reaction proceeds via a substitution nucleophilic aromatic (SNAr) mechanism 
(see Fig 38 on the next page).  This involves a two step process in which the first step 
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involves the attack of the nucleophilic amine (in this case the 2o cyclic amine 
piperazine) on the heteroaryl halide (in this case 4,7-DCQ) to give a resonance 
stabilised carbanion intermediate.  The formation of this intermediate is often the rate 
limiting step.  This is followed by the loss of the halide leaving group (chloride) in the 
second step. 
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Figure 38 Proposed SNAr mechanism for the reaction of 4,7-DCQ & piperazine 
 
Bases catalyse the above process by increasing the rate of the second step .89  Under 
protic solvent conditions, it is generally believed that base catalysts function by 
deprotonating the quaternary amino group of the intermediate followed by the rapid 
loss of the chloride. The base may also assist the loss of chloride directly via a 
protonated form of the base catalyst (conjugate acid).89 
 
Most published methods for the synthesis of similar compounds use an excess of 
piperazine76,77 or other diamine when coupling with 4,7-DCQ and therefore the 
unreacted piperazine functions as an organic base. A 4,7-DCQ : piperazine molar ratio 
of 1:5 was employed in our first attempt (Figure 23) as presented for the method 
published by Clarkson et al (synthesis of Totarol amino alcohol derivatives).77 
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However, the quantities of both reactants were relatively high in comparison to the 
second base/solvent (Et3N) used and therefore complete dissolution of the reactants in 
the basic solvent was not achieved. The material obtained after work up was a hard 
dark brown resinous solid soluble in DCM.  TLC analysis on the substance showed 
multiple compound spots. Flash column chromatography was performed but, this 
procedure was not wholly successful. Most of the piperazine originally present in the 
reaction mixture was removed by the chromatographic purification step but 4,7-DCQ 
still remained. The presence of TLC spots of very close proximity meant that the 
amounts of fractions containing the suspect product were also contaminated with 
impurities.  However, the 1H NMR spectrum (CDCl3) of these fractions showed 
mostly presence of 4,7-DCQ (trace quantities of water, ethanol and silicone grease 
were also present).  Reference spectra from the literature were compared with the 
spectrum obtained to clarify and confirm the above conclusions.63, 76,77. The lack of 
reactant solvation might be one possible reason why this reaction failed.  The lower 
reaction temperature of 80°C was selected (compared to the higher temperatures used 
in other literature methods) to avoid charring and degradation of the reactants because 
they were not in solution.  This lower temperature obviously avoided compound 
degradation but meant the reaction had to be carried out over a longer period (48 
hours). The lower temperature may also have played a significant role in the 
reaction’s failure.   
 
The second attempt at the coupling of 4,7-DCQ with piperazine was similar to the 
above method except for the use of triethylamine base in N-methyl-2-pyrrolidinone 
solvent (see Figure 24, Page 38).  This attempt was based on the method by Beagley 
et al in which triethylamine and N-methyl-2-pyrrolidinone were used in the molar 
ratio 3:7 for a similar synthetic reaction (synthesis of ruthenocene-chloroquine 
analogues).91  The same reaction conditions were further cited by Chiyanzu et al using 
triethylamine, K2CO3 and N-methyl-2-pyrrolidinone (for 4 hours at 135ºC).76 
 
After 48 hours at 80ºC, TLC analysis performed on the reaction mixture showed the 
formation of a new product which was subsequently purified using a basic work up.  
A basic work up with NaOH was employed as it was believed that the product formed 
was an HCl salt (the reaction produces two molar equivalents of HCl as by-product).  
To generate the free piperazinyl base, a stronger base (NaOH) is added which 
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displaces the weak base product from its salt.  The free amino base can then be 
extracted into an organic solvent i.e. DCM.  Saturated brine was used in the work up 
for two reasons.  Brine is used to dry the organic phase and restricts the dissolution of 
the free base into the aqueous phase.  After work up, the shiny chocolate coloured 
compound afforded was analysed by 1H NMR spectroscopy.  However, the spectrum 
showed peaks pertaining to N-methyl-2-pyrrolidinone only. Neither the starting 
materials (4,7-DCQ and piperazine) nor the desired product were present.   
 
The third attempt at the coupling of 4,7-DCQ with piperazine was based (partly) on 
the previously described attempts and the success of a similar reaction with tBOC 
protected piperazine which will be discussed in the later section  (see Figure 25, Page 
39).82  The use of diisopropyl ethylamine (DIPEA) as a solvent-base was described in 
two recent literature methods describing the coupling of 4,7-DCQ with aminoheptanes 
and aminopiperidine.78, 96  These methods describe the coupling of 4,7-DCQ with 4-
aminopiperidine (Madrid et al 78) using DIPEA as a solvent-base (100°C for 20 hours) 
and the synthesis of antiprion polyquinoline derivatives (Klingenstein et al).96  In this 
latter method, 4,7-DCQ was coupled with diaminoheptane in the presence of DIPEA 
using 1-pentanol as a solvent.96  Piperazine reacts with 4,7-DCQ in a similar fashion 
to the compounds mentioned above, though the molar ratios of the reactants might not 
be similar.  After careful review of the methods it was decided that a ratio of 1:5 (4,7-
DCQ: piperazine) would be used for our reaction.76,77  This ratio was selected to 
primarily minimise the formation of bis- substituted by-product.  As has been 
mentioned earlier, most previous research methods describing similar coupling 
reactions of 4,7-DCQ and secondary and tertiary amines have utilized the ratio of 1:3 
or more.76, 77, 82  In addition, the use of catalytic amounts of potassium iodide (KI) as 
described by Kumar et al is known to increase the efficiency of nucleophilic 
substitution reactions.82 They have claimed that the molar ratio of the reactants can be 
decreased from 1:5 to 1:1 when KI is employed as a catalyst.  Potassium iodide 
catalyses the reaction by substitution of the chorine atom on the quinoline ring (4-
chloro site) with an iodine atom, to form a stable iodide intermediate.  Iodide is 
subsequently displaced more readily than chloride due to the weak carbon-halogen 
bond thus making the nuclear carbon (C-4) more prone to nucleophilic substitution by 
the amine.93 
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 Therefore, in our third attempt at the coupling reaction of piperazine and 4,7-DCQ 
the solvent-base used was DIPEA and catalytic amounts of KI were added.  The 
reaction produced a dark brown substance which was purified via a basic work up.  
However, as in previous attempts the procedure generated a shiny chocolate coloured 
solid with an 1H NMR spectrum (CDCl3) that showed the presence of 4,7-DCQ 
only(minute quantities of solvent impurities were also observed).  
 
The fourth and final attempt at the coupling of 4,7-DCQ with piperazine was based 
directly on a published method by Clarkson et al (See Figure 26, Page 40).77  As 
mentioned at the beginning of this chapter, three different research groups had 
synthesized 7-chloro-4-[piperazin-1-yl]quinoline previously using fairly similar 
approaches.  The method described by Clarkson et al which coupled 4,7-DCQ with 
piperazine in a 1:5 ratio in presence of K2CO3 and triethylamine was selected for the 
present research.77  All the steps in the procedure including the work up with 4:1 
DCM: MeOH and column chromatography were repeated as described in the 
literature method.  However, the 1H NMR spectrum (CDCl3) of the pale yellow oil 
that was formed did not show any peaks for the desired product, but indicated the 
presence of piperazine only. The reason for the reaction’s failure could not be 
determined, bearing in mind that the procedure was reproduced exactly. Due to time 
constraints, no further investigation or repeat of this reaction was attempted.  
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3.3.2  Coupling Reaction of 4,7-DCQ and tBOC-Piperazine  
The problems of direct coupling of piperazine with 4,7-DCQ have been discussed in 
the sections above (Section 3.1.1 and 3.1.2).  One of the strategies to overcome these 
issues, as mentioned earlier is to protect piperazine with a suitable protecting group. 
In this section, the attempted coupling reactions of tBOC-piperazine with 4,7-DCQ 
are discussed.  As mentioned earlier, tBOC-piperazine is a commercially available 
substance therefore no attempts were made to synthesise this compound in our 
laboratory.  
 
Two methods were made to couple 4,7-DCQ with tBOC-piperazine (Pages 41 and 42).  
The first method was partly based on a literature method described by Madrid et al.78  
They coupled 4,7-DCQ with 4-aminopiperidine using DIPEA as a solvent-base at 
1000C for 20 hours.78  In our first attempt, DIPEA was used as the solvent and the 
reaction conditions were virtually unchanged except a milder reaction temperature of 
80°C (for 48 hours) was employed(see Figure 27, Page 41).  DIPEA was used for its 
better solubility as reported by Madrid and Klingenstein et al.78,96 However, the use of 
tBOC-piperazine in the present research meant that there was very little scope for the 
formation of a bis substituted product unless deprotection occurred in the reaction 
flask.  This later scenario is highly unlikely since strongly acidic conditions are 
required for this to occur. 4,7-DCQ and tBOC-piperazine were mixed in the molar 
ratio of 1:1.  This was based on the assumption that with only one available site on 
tBOC-piperazine for nucleophilic aromatic substitution it would react quantitatively 
with 4,7-DCQ.  This is in contrast to previous literature methods which have reacted 
protected amines in a higher molar ratio while coupling them with 4,7-DCQ. These 
include a method by Solomon et al in which mono-BOC-protected diaminoalkanes 
and 4,7-DCQ were reacted in the molar ratio 1:2.94  After completion of the reaction, 
a shiny chocolate coloured solid was obtained.  The 1H NMR spectrum (CDCl3) of 
this solid showed peaks for the desired product. But 4,7-DCQ and tBOC-piperazine 
were also evident. The 9H singlet for tBOC at δ 1.45 ppm was larger than expected 
and the 12H isopropyl doublet normally observed for DIPEA (observed at δ 1-2 ppm) 
appeared to be overlapping with the product tBOC singlet.  Another possible reason 
for the extension of this singlet could be the presence of unreacted tBOC-piperazine.  
Flash column chromatography was performed on the crude solid and 1H NMR spectral 
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analysis performed on the solid obtained after the purification showed the product was 
present; but that impurities such as 4,7-DCQ, tBOC-piperazine and DIPEA were also 
evident. 
 
 The second attempt was similar to the above reaction except for the use of a catalytic 
amount of KI (see Page 42).  After refluxing for 48 hours at 80°C in DIPEA, TLC 
analysis showed almost no traces of starting material.  A work up procedure based on 
earlier reactions was used to purify the crude product (Section 3.3.1). The 1H NMR 
spectrum (CDCl3) on the solid obtained showed that the desired product, 7-chloro-4-
(tBOC piperazin-1-yl)quinoline had been successfully synthesized with only minor 
impurities present.   The reaction yield was approximately 46 % (including minor 
impurities). The following table lists the product peaks that were observed for 7-
chloro-4-(tBOC piperazin-1-yl)quinoline.  
 
Table 1  Peak interpretation results for 7-chloro-4-(tBOC piperazin-1-
yl)quinoline 
 
Chemical shift  (δ) Peak type Proton Assignment 
8.61 Doublet 1H H-2 
8.40 Doublet 1H H-8 
7.94 Doublet 1H H-5 
7.50 Doublet of doublet 1H H-6 
6.95 Doublet 1H H-3 
3.72 Multiplet 4H 2×H-51&31 
3.43 Multiplet 4H 2×H-21&61 
1.50 Singlet 9H tBOC (3×CH3) 
 
 
3.3.2.1 Deprotection of 7-chloro-4-(tBOC piperazin-1-yl) quinoline 
The next step required the deprotection of 7-chloro-4-(tBOC piperazin-1-yl)quinoline 
afforded in the previous coupling reaction, to remove the tertiary butoxy carbonyl 
group (See Page 43).  The deprotected product 7-chloro-4-(piperazin-1-yl)quinoline 
would subsequently be coupled by reacting with 1,3-dichloropropanol (1,3-DCP) for 
the final synthesis of HPQ.  Various methods for the deprotection of the tBOC group 
have been described in the literature.65,66  The procedure should be achievable under 
relatively mild conditions using strong acids such as HCl and trifluoroacetic acid 
(TFA) in the presence or absence of DCM as solvent.67,87  Fray et al describe a 
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method for the deprotection of N-Boc-piperazine using 50% TFA: DCM at 20ºC for 
30 mins.67, 87, 88 The use of HCl and ethyl acetate was described by Stahl et al.97  
Solomon et al deprotected the N-Boc-protected derivatives of 4-aminoquinolines 
using 20% HCl in dioxane.94  In the present work, a 50% (v/v) TFA: DCM mixture 
was used to deprotect 7-chloro-4-(tBOC piperazin-1-yl)quinoline.  The end products 
from the successful coupling reactions described above (section 3.3.2) were stirred 
separately with 50% (v/v) TFA: DCM at room temperature for 15 mins.  The method 
appeared to be very efficient because 1H NMR spectral analysis of the solid after 
work up showed only deprotected product. The reaction yield for the deprotection step 
was 65 %.   Trace quantities of DCM were present along with two broad peaks at   δ 
4.00 ppm and δ 3.90 ppm and a triplet at δ 3.35 ppm. These impurity peaks were also 
common to other spectra obtained in our laboratory using the same source of NMR 
solvent (CDCl3) and represent an inert contaminant in the solvent bottle. The 
following table lists the product peaks that were observed for 7-chloro-4-(piperazin-1-
yl)quinoline.  
 
Table 2 Peak interpretation results for 7-chloro-4-( piperazin-1-yl)quinoline 
 
Chemical shift  (δ) Peak type Proton Assignment 
8.61 Doublet 1H H-2 
8.40 Doublet 1H H-8 
7.94 Doublet 1H H-5 
7.50 Doublet of doublet 1H H-6 
6.95 Doublet 1H H-3 
4.00 Multiplet 8H 2H at 21, 61, 51& 31 
3.2 Multiplet 1H H-41 
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3.4 Synthesis of Hydroxypiperaquine (HPQ) 
Following on from the successful synthesis of the intermediate 7-chloro-4-(piperazin-
1-yl) quinoline, described in the previous section the next synthetic step planned was 
to couple this compound with 1,3-dichloropropanol to generate HPQ (see Page 24).  
Four separate attempts were made to synthesize HPQ (see Pages 44-48).  Two 
different approaches based on literature methods were initially attempted.63, 82  The 
first approach using an organic base; was based on a similar nucleophilic substitution 
reaction discussed in the above section (Section 3.3).  The second approach utilised 
inorganic bases such as potassium carbonate and sodium carbonate in various solvents.  
 
3.4.1 Synthesis of HPQ in organic base 
The first attempted synthesis of HPQ in DIPEA was based on literature methods as 
described by Madrid et al and Klingenstein et al.78, 96  The method described by 
Madrid et al did not employ solvent, but instead used large quantities of DIPEA as 
base and solvent.78  In the present work, the coupling of 7-chloro-4-(piperazin-1-
yl)quinoline with  1,3-dichloropropanol was performed in N-methylpyrrolidinone  
(NMP) with DIPEA and Et3N as the bases (see Page 44).  Catalytic amounts of KI 
were used according to Kumar’s method.82  The reaction was carried out at reflux for 
24 h.  The 1H NMR spectrum (CDCl3) of the pale chocolate coloured solid obtained 
was compared to reference data for HPQ from the review published by Xu et al.3  
However, the spectrum obtained indicated that the above reaction was not successful. 
The spectrum showed peaks pertaining to NMP, 1,3-DCP and trace quantities of 
DCM only. 
 
3.4.2 Synthesis of HPQ in an inorganic base 
The first attempt using an inorganic base (see Page 45) was based on the synthesis of 
hydroxychloroquine as described by Kumar et al.82 The reactants (7-chloro-4-
(piperazin-1-yl)quinoline and 1,3-dichloropropanol)  were refluxed in the presence of 
K2CO3 and KI for 48 hours in isopropanol.76,77,91  However, the 1H NMR spectrum for 
the crude compound given showed only peaks for solvent and water.  The sample was 
reanalysed after a basic work up procedure but, the spectrum for the obtained residue 
only showed peaks for chloroform and water.  
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 The second attempt using an inorganic base (see Page 46) was based on the synthesis 
of bis (4-(7-chloroquinolin-4-yl) piperazin-1-yl)methane described by Vennerstrom et 
al (Figure 38).  This compound is very similar in structure to HPQ and was 
synthesised by reacting 7-chloro-4-(piperazin-1-yl)quinoline with formaldehyde in 
methanol at room temperature.63  
 
N
NN
N
N
Cl
N
Cl
 
 
Figure 39 Structure of Bis(4-(7-chloroquinolin-4-yl) piperazin-1-yl)methane 
 
In our attempt to synthesize HPQ from 7-chloro-4-(piperazin-1-yl)quinoline similar 
reaction conditions were employed to that described for the synthesis of the above 
compound.  However, the 1HNMR spectrum for the dark brown oily liquid obtained 
did not show any peaks for HPQ and only 1,3-DCP was present.  
  
The third attempt using K2CO3 (see Page 47) was based on a method described by 
Ryckebusch et al.92  They synthesized a range of piperazine derivatives via 
nucleophilic substitution reactions of 4,7-DCQ with bis-(3-aminopropyl)piperazine in 
1-pentanol (amyl alcohol).  This solvent has been previously used by Fong in our 
laboratory for the attempted synthesis of HPQ.64  The reactants were refluxed for 14 
hours at 120ºC with K2CO3. Following purification of the crude solid obtained by 
column chromatography the reaction yielded a brownish yellow solid which contained 
minute impurities. The 1H NMR spectrum (CDCl3) for the brownish yellow solid was 
compared to the spectrum described by Xu et al3 and this conformed that HPQ was 
present in a crude form. The partial success of this reaction can possibly be attributed 
to 1-pentanol. Pentanol is a high molecular weight alcohol and is more lipophilic/less 
polar resulting in lower solvation of the nucleophile (similar to aprotic solvents).93 
This would allow it to possibly react more efficiently than the previous alcohols used 
in the first two attempts. The following table lists the product peaks that were 
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observed for HPQ. Apart from these peaks, trace amounts of DCM and 1-pentanol 
were observed in the spectrum.  
 
Table 3 Peak interpretation results for HPQ 
 
Chemical shift (δ) Peak type Proton Assignment 
8.71 Doublet 2H H-2 × 2 
8.10 Doublet 2H H-8 × 2 
7.97 Doublet 2H H-5 × 2 
7.49 Doublet of doublet 2H H-6 × 2 
6.88 Doublet 2H H-3 × 2 
4.10 Pentat 1H CH-OH 
3.60 Broad singlet 1H OH 
3.40 Broad singlet 8H 2 × 2H at 21 and 61piperazine 
2.80 Singlet 8H 2 × 2H at 51 and 31piperazine 
2.30 Doublet 4H CH2-propanol × 2 
 
 
Though impurities were present in the final product, future attempts at the synthesis of 
HPQ then using an improved chromatographic purification and recrystallisation 
should yield a product of relatively high purity. It was planned at the start of the 
research program that upon successful completion of each synthetic step, each step 
would be reproduced and possibly modified to further optimize the reactant 
proportions, solvent and base quantities. This would have resulted in a final synthetic 
route with improved product yields. The above optimization process could not be 
undertaken due to time restrictions. However, this research is a part of ongoing work 
at the School of Pharmacy (Curtin University of Technology) to explore the synthesis 
of HPQ and will endeavour to undertake this optimization process.  
 
The final synthetic approach to HPQ synthesis in this research was achieved via a 
three step synthetic process (Figure 39). In the first step, commercially available 
tBOC piperazine was coupled with 4,7-DCQ in a molar ratio of 1:1 in presence of KI 
in DIPEA at reflux for 48 hours. The reaction produced the intermediate compound 7-
chloro-4-(tBOC piperazin-1-yl)quinoline (46 % yield). The introduction of tBOC 
piperazine as the starting material was crucial and prevented the past major 
complication arising from contamination of the product with excess piperazine.   
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Figure 40 Three step synthetic route to HPQ 
 
 
The second synthetic step involved the deprotection of                                                       
7-chloro-4-(tBOC piperazin-1-yl)quinoline to remove the tBOC protecting group and 
render the amine site on the piperazine molecule free for nucleophilic substitution 
reaction with 1,3-DCP. This was achieved cleanly and efficiently by deprotection with 
TFA: DCM mixture (50% (v/v)). (65 % yield)  
 
The deprotected intermediate (7-chloro-4-(piperazin-1-yl)quinoline) was then reacted 
with 1,3-DCP using K2CO3 in 1-pentanol to generate HPQ.  The reaction was 
performed with a 2:1 molar equivalent ratio of the reactants at 120ºC for 14 hours(59 
% yield)  1-Pentanol proved an ideal solvent, dissolving both starting materials with 
ease and permitting the desired high reflux temperature for reaction to occur 
efficiently. However, even after chromatographic purification, the product (HPQ) 
synthesised was not completely free from solvent impurities (DCM and 1-pentanol). 
Unfortunately due to time constraints this step was not optimised and neither was any 
effort made to improve the purification procedure. 
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4  CONCLUSIONS 
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It is estimated that over 40% of the world’s population is exposed to malaria and 270 
million of those exposed are infected with malarial parasites. 13  The emergence and 
spread of drug-resistant malarial parasites has become a major global issue because 
chemotherapy remains the most important means of controlling malaria. 16,18  
Therefore the development of novel drugs and drug combinations to replace older 
drugs is imperative. 
 
Hydroxypiperaquine (HPQ) is a bisquinoline antimalarial drug which displays very 
similar antimalarial activity to its parent compound piperaquine (PQ).3  HPQ as an 
antimalarial has potentially numerous advantages over piperaquine.  The additional 
hydroxyl group in HPQ appears to make it a prime candidate for Phase 2 metabolic 
processes e.g. glucuronidation, which should increase its clearance rate thus reducing 
its biological half life (piperaquine has a very long biological half life).  This may 
lower the probability of drug resistance.  The additional hydroxyl group should also 
be readily derivatized to afford a range of simple ester prodrugs in order to address a 
range of pharmaceutical issues.68,69 
 
The primary aim of this research project was to synthesise HPQ via alternative 
synthetic pathways to that briefly described in the literature.3  The major objectives of 
the research program were to explore various synthetic strategies based on literature 
synthetic procedures involving similar compounds.  In this study, various synthetic 
approaches, employing a variety of reaction conditions, reactants, catalyst and 
solvents were trailed in attempts to achieve the synthesis of HPQ. The success and 
efficacy of experiments performed were assessed via 1H NMR spectroscopy and TLC 
exclusively. 
 
Initial synthetic approaches attempted to synthesize the intermediate 1,3-(bis 
piperazinyl)-propan-2-ol from 1,3-DCP and protected piperazine. Protected 
piperazines such as 1-benzylpiperazine and tBOC piperazine were employed. 
However, this strategy was not successful. After the failure of this approach, the 
synthesis of the intermediate 7-chloro-4-(piperazin-1-yl)quinoline from 4,7-DCQ via 
a tBOC protected piperazine was achieved. The synthesis of HPQ was finally 
achieved by reaction of the deprotected intermediate with 1,3-dichloropropanol using 
K2CO3 in 1-pentanol. 
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The scheme below illustrates the final three step synthetic route for the synthesis of 
hydroxypiperaquine (HPQ). 
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Figure 41 Summary of HPQ synthesis (Three step synthetic route to HPQ) 
 
In conclusion, the above synthetic approach provides a relatively efficient process for 
the synthesis of HPQ from relatively accessible starting materials and reagents.  
However, further refinement and optimization of the reaction conditions and reactant 
proportionalities will be required. The use of time consuming column chromatography 
could possibly be replaced by recrystallisation to afford the compound in a very high 
level of purity. Unlike the previously reported synthesis of HPQ by Xu et al3, this 
research provides specific details of the synthetic methodology involved for the 
synthesis of HPQ.   
 
46.0% 
59.0% 
64.7% 
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6  APPENDICES 
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Figure 42 1H NMR spectrum (CDCl3) for the reaction 2.1.2.1 
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Figure 43 1H NMR spectrum (CDCl3) for the reaction 2.1.2.2 
 
 89 
Figure 44 1H NMR spectrum (CDCl3) for the reaction 2.1.2.3 
 
 90 
Figure 45 1H NMR spectrum (CDCl3) for the reaction 2.1.2.5 
 
 91 
Figure 46 1H NMR spectrum (CDCl3) for the reaction 2.1.2.6 
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Chemical shift  (δ) Peak type Proton Assignment 
8.61 Doublet 1H H-2 
8.40 Doublet 1H H-8 
7.94 Doublet 1H H-5 
7.50 Doublet of doublet 1H H-6 
6.95 Doublet 1H H-3 
3.72 Multiplet 4H H-51&31 
3.43 Multiplet 4H H-21&61 
1.50 Singlet 9H tBOC (3×CH3) 
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Figure 47 Peak interpretation results and numbered structure of 7-chloro-4-(tBOC piperazin-1-yl)quinoline 
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Figure 48 1H NMR spectrum (CDCl3) for the reaction 2.1.2.7 
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Chemical shift  (δ) Peak type Proton Assignment 
8.61 Doublet 1H H-2 
8.40 Doublet 1H H-8 
7.94 Doublet 1H H-5 
7.50 Doublet of doublet 1H H-6 
6.95 Doublet 1H H-3 
3.43 Multiplet 8H 2H ×(H-21& 31, 51&61) 
1.50 Singlet 1H H-41 
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Figure 49 Peak interpretation results and numbered structure of 7-chloro-4-( piperazin-1-yl)quinoline 
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Figure 50 1H NMR spectrum (CDCl3) for the reaction   2.1.3.1 
 
 96 
Figure 511H NMR spectrum (CDCl3) for the reaction 2.1.3.2 
 
 97 
Figure 52 1H NMR spectrum (CDCl3) for the reaction 2.1.3.3 
 
 98 
Figure 53 1H NMR spectrum (CDCl3) for the reaction 2.1.3.4 
 
 99 
Chemical shift (δ) Peak type Proton Assignment 
8.71 Doublet 2H H-2 × 2 
8.10 Doublet 2H H-8  ×2 
7.97 Doublet 2H H-5  ×2 
7.49 Doublet of doublet 2H H-6  ×2 
6.88 Doublet 2H H-3  ×2 
4.10 Pentet 1H CHOH 
3.60 Broad singlet 1H OH 
3.40 Broad singlet 8H 2H ×(21 and 31piperazine) 
2.80 Singlet 8H 2H ×(51 and 61piperazine) 
2.30 Doublet 4H CH2-propanol  ×2 
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Figure 54 Peak interpretation results and numbered structure of HPQ 
 
